CN110156656B - Five-membered heteroaromatic ring derivative, preparation method thereof, pharmaceutical composition and application - Google Patents
Five-membered heteroaromatic ring derivative, preparation method thereof, pharmaceutical composition and application Download PDFInfo
- Publication number
- CN110156656B CN110156656B CN201910062130.0A CN201910062130A CN110156656B CN 110156656 B CN110156656 B CN 110156656B CN 201910062130 A CN201910062130 A CN 201910062130A CN 110156656 B CN110156656 B CN 110156656B
- Authority
- CN
- China
- Prior art keywords
- substituted
- compound
- cancer
- unsubstituted
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000001072 heteroaryl group Chemical group 0.000 title claims abstract description 65
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 12
- 230000009385 viral infection Effects 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 150
- -1 methoxy, trifluoromethoxy, ethoxy Chemical group 0.000 claims description 127
- 238000006243 chemical reaction Methods 0.000 claims description 100
- 125000000217 alkyl group Chemical group 0.000 claims description 76
- 125000003545 alkoxy group Chemical group 0.000 claims description 41
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 37
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 34
- 229910052736 halogen Inorganic materials 0.000 claims description 33
- 150000002367 halogens Chemical class 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 32
- 125000001424 substituent group Chemical group 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 29
- 125000005843 halogen group Chemical group 0.000 claims description 27
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- 239000003513 alkali Substances 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 238000006482 condensation reaction Methods 0.000 claims description 5
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 claims description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 3
- 241000701806 Human papillomavirus Species 0.000 claims description 3
- 229940113303 Indoleamine 2,3-dioxygenase inhibitor Drugs 0.000 claims description 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 241000709687 Coxsackievirus Species 0.000 claims description 2
- 241000991587 Enterovirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 2
- 206010029491 Nodular vasculitis Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 230000006052 T cell proliferation Effects 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 abstract description 23
- 239000000651 prodrug Substances 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 15
- 230000005764 inhibitory process Effects 0.000 abstract description 13
- 206010062016 Immunosuppression Diseases 0.000 abstract description 7
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 156
- 239000000243 solution Substances 0.000 description 74
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 47
- 230000015572 biosynthetic process Effects 0.000 description 43
- 238000003786 synthesis reaction Methods 0.000 description 42
- 239000012074 organic phase Substances 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 239000007787 solid Substances 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- 239000003112 inhibitor Substances 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 230000002829 reductive effect Effects 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 238000003818 flash chromatography Methods 0.000 description 23
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 22
- 238000005481 NMR spectroscopy Methods 0.000 description 22
- 125000004093 cyano group Chemical group *C#N 0.000 description 22
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 239000003208 petroleum Substances 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 20
- 125000003118 aryl group Chemical group 0.000 description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 230000014759 maintenance of location Effects 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 238000001308 synthesis method Methods 0.000 description 14
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 13
- 230000000155 isotopic effect Effects 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 11
- 238000002953 preparative HPLC Methods 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 10
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 229910052805 deuterium Inorganic materials 0.000 description 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 229960004799 tryptophan Drugs 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 125000003373 pyrazinyl group Chemical group 0.000 description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- VCUXURBVRXWSQQ-UHFFFAOYSA-N 2-bromo-1-(1-methylcyclopropyl)ethanone Chemical compound BrCC(=O)C1(C)CC1 VCUXURBVRXWSQQ-UHFFFAOYSA-N 0.000 description 6
- WCCCDMWRBVVYCQ-UHFFFAOYSA-N 2-bromo-1-cyclopropylethanone Chemical compound BrCC(=O)C1CC1 WCCCDMWRBVVYCQ-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 6
- 210000001853 liver microsome Anatomy 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 6
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 5
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 5
- JXASPPWQHFOWPL-UHFFFAOYSA-N Tamarixin Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 JXASPPWQHFOWPL-UHFFFAOYSA-N 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940125797 compound 12 Drugs 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 125000003226 pyrazolyl group Chemical group 0.000 description 5
- 125000002098 pyridazinyl group Chemical group 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 4
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- VQFAIAKCILWQPZ-UHFFFAOYSA-N bromoacetone Chemical compound CC(=O)CBr VQFAIAKCILWQPZ-UHFFFAOYSA-N 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940125810 compound 20 Drugs 0.000 description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- 238000013100 final test Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 3
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 3
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 3
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 3
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 3
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 3
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- UTWKJAQRVLPKFU-UHFFFAOYSA-N 1-bromo-3-hydroxy-3-methylbutan-2-one Chemical compound CC(C)(O)C(=O)CBr UTWKJAQRVLPKFU-UHFFFAOYSA-N 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- GARMSXYJABHUGJ-UHFFFAOYSA-N BrCC(=O)C1CN(C1)C(=O)OCC1=CC=CC=C1 Chemical compound BrCC(=O)C1CN(C1)C(=O)OCC1=CC=CC=C1 GARMSXYJABHUGJ-UHFFFAOYSA-N 0.000 description 3
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229940043367 IDO1 inhibitor Drugs 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940076788 pyruvate Drugs 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 2
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- ZADWXFSZEAPBJS-UHFFFAOYSA-N 1-methyltryptophan Chemical compound C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 description 2
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 2
- UCVGCGJYBNVWKZ-UHFFFAOYSA-N 3-(trifluoromethoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=C1OC(F)(F)F UCVGCGJYBNVWKZ-UHFFFAOYSA-N 0.000 description 2
- BNDRWEVUODOUDW-UHFFFAOYSA-N 3-Hydroxy-3-methylbutan-2-one Chemical compound CC(=O)C(C)(C)O BNDRWEVUODOUDW-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- KRNSYSYRLQDHDK-UHFFFAOYSA-N 6,7-dihydro-5h-cyclopenta[b]pyridine Chemical compound C1=CN=C2CCCC2=C1 KRNSYSYRLQDHDK-UHFFFAOYSA-N 0.000 description 2
- FAUXVMHIRXXEHI-UHFFFAOYSA-N 6-chloro-3-(trifluoromethoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(Cl)=CC=C1OC(F)(F)F FAUXVMHIRXXEHI-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 102000003915 DNA Topoisomerases Human genes 0.000 description 2
- 108090000323 DNA Topoisomerases Proteins 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BYHJHXPTQMMKCA-QMMMGPOBSA-N N-formyl-L-kynurenine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)C1=CC=CC=C1NC=O BYHJHXPTQMMKCA-QMMMGPOBSA-N 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical group [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- JTPFMKCZHHMBIK-UHFFFAOYSA-N [N+](=[N-])=CC(=O)C1CN(C1)C(=O)OCC1=CC=CC=C1 Chemical compound [N+](=[N-])=CC(=O)C1CN(C1)C(=O)OCC1=CC=CC=C1 JTPFMKCZHHMBIK-UHFFFAOYSA-N 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical class C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- NVOLYUXUHWBCRJ-UHFFFAOYSA-N (2-methoxypyridin-3-yl)boronic acid Chemical compound COC1=NC=CC=C1B(O)O NVOLYUXUHWBCRJ-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- VKRKCBWIVLSRBJ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC21OCCO2 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 description 1
- OQBCJXUAQQMTRW-UHFFFAOYSA-N 1-(1-methylcyclopropyl)ethanone Chemical compound CC(=O)C1(C)CC1 OQBCJXUAQQMTRW-UHFFFAOYSA-N 0.000 description 1
- HQHMVIUGJYTFRA-UHFFFAOYSA-N 1-(oxetan-3-yl)ethanone Chemical compound CC(=O)C1COC1 HQHMVIUGJYTFRA-UHFFFAOYSA-N 0.000 description 1
- 125000006420 1-fluorocyclopropyl group Chemical group [H]C1([H])C([H])([H])C1(F)* 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PVJPBKZGIUAESY-UHFFFAOYSA-N 1-phenylmethoxycarbonylazetidine-3-carboxylic acid Chemical compound C1C(C(=O)O)CN1C(=O)OCC1=CC=CC=C1 PVJPBKZGIUAESY-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 1
- FMKOJHQHASLBPH-OUBTZVSYSA-N 2-iodopropane Chemical group CC([13CH3])I FMKOJHQHASLBPH-OUBTZVSYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 1
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- YYOMGJUZUCMMQW-UHFFFAOYSA-N 4-(2-methoxypyridin-3-yl)-5-methyl-1H-pyrrole-3-carboxylic acid Chemical compound CC1=C(C(=CN1)C(=O)O)C2=C(N=CC=C2)OC YYOMGJUZUCMMQW-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- CKTQPWIDUQGUGG-UHFFFAOYSA-N 4-chloro-6-fluoroquinoline Chemical compound N1=CC=C(Cl)C2=CC(F)=CC=C21 CKTQPWIDUQGUGG-UHFFFAOYSA-N 0.000 description 1
- DYAWMXSWDGPGOI-UHFFFAOYSA-N 4-hydroxy-3,3-dimethylbutan-2-one Chemical group CC(=O)C(C)(C)CO DYAWMXSWDGPGOI-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001455214 Acinonyx jubatus Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 102100031934 Adhesion G-protein coupled receptor G1 Human genes 0.000 description 1
- 241001251200 Agelas Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- MWWDRMMCBFKTGD-UHFFFAOYSA-N CC1=CC(=C(N1CCO)C2=C(C=CC=N2)OC(F)(F)F)C(=O)O Chemical compound CC1=CC(=C(N1CCO)C2=C(C=CC=N2)OC(F)(F)F)C(=O)O MWWDRMMCBFKTGD-UHFFFAOYSA-N 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical group [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- 101710121810 Galectin-9 Proteins 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000775042 Homo sapiens Adhesion G-protein coupled receptor G1 Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 description 1
- 101000831286 Homo sapiens Protein timeless homolog Proteins 0.000 description 1
- 101000752245 Homo sapiens Rho guanine nucleotide exchange factor 5 Proteins 0.000 description 1
- 101000669511 Homo sapiens T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 description 1
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 102100035487 Nectin-3 Human genes 0.000 description 1
- 206010029132 Nephritis haemorrhagic Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 101150094373 Padi4 gene Proteins 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000498819 Protula Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010042970 T-cell chronic lymphocytic leukaemia Diseases 0.000 description 1
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 description 1
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 description 1
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 229940122429 Tubulin inhibitor Drugs 0.000 description 1
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- YQYBUJYBXOVWQW-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1CC2=CC=CC=C2CC1 YQYBUJYBXOVWQW-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000018093 autoimmune cholangitis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- UMIVXZPTRXBADB-UHFFFAOYSA-N benzocyclobutene Chemical compound C1=CC=C2CCC2=C1 UMIVXZPTRXBADB-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 125000004586 dihydrobenzopyranyl group Chemical group O1C(CCC2=C1C=CC=C2)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002944 hormone and hormone analog Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 101150091799 ido gene Proteins 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- QVGXLLKOCUKJST-NJFSPNSNSA-N oxygen-18 atom Chemical group [18O] QVGXLLKOCUKJST-NJFSPNSNSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- WWTULTKUWBKVGV-UHFFFAOYSA-M potassium;3-methoxy-3-oxopropanoate Chemical compound [K+].COC(=O)CC([O-])=O WWTULTKUWBKVGV-UHFFFAOYSA-M 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical class [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 229940076376 protein agonist Drugs 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention discloses a five-membered heteroaromatic ring derivative, a preparation method, a pharmaceutical composition and application thereof. The five-membered heteroaromatic ring derivative (I), an isomer, a prodrug, a stable isotope derivative or a pharmaceutically acceptable salt thereof has the following structure. The five-membered heteroaromatic ring derivative has good IDO inhibition effect, and can effectively treat, relieve and/or prevent various related diseases caused by immunosuppression, such as tumors, virus infection or autoimmune diseases.
Description
Technical Field
The invention relates to a five-membered heteroaromatic ring derivative, a preparation method, a pharmaceutical composition and application thereof.
Background
Indoleamine 2,3-dioxygenase (IDO), an immunomodulatory enzyme produced by a number of alternatively activated macrophages and other immunoregulatory cells (also used by many tumors as a strategy to destroy immunity), is encoded by the IDO gene in humans. Its function is to break down the essential L-tryptophan to kynurenine (kynurenine). Depletion of tryptophan and its metabolites results in strong suppression of the immune response, resulting in the cessation of T cell growth, blocking T cell activation, inducing T cell apoptosis and increasing the production of regulatory T cells. The pathway from tryptophan to kynurenine metabolism is now established as a key regulatory pathway for innate and adaptive immunity.
Numerous preclinical studies have shown that this immune tolerance pathway is active in tumor immunity, autoimmunity, infection, transplant rejection, and allergy. The increased activity of IDO in cancer cells is now recognized as an important factor in cancer proliferation and metastasis. Studies have shown that IDO inactivates tumor-specific cytotoxic T lymphocyte functions or is no longer able to attack cancer cells of patients, and in fact, many human cancers, such as prostate, colorectal, pancreatic, cervical, gastric, ovarian, brain, lung, etc., overexpress human IDO. The inhibition of IDO can reverse the inhibition of tumor to human immune function, thereby generating an effective anti-tumor immune response. Since IDO inhibitors can activate T cells and thereby enhance immune function in humans, IDO inhibitors have therapeutic effects on a number of diseases, including tumor resistance and rejection, chronic infections, HIV infection and aids, autoimmune diseases or disorders, such as rheumatoid arthritis, immune tolerance and prevention of intrauterine fetal rejection. Inhibitors of IDO may also be useful in the treatment of neurological or neuropsychiatric diseases or disorders, such as depression (Protula et al, 2005, blood, 106.
A large number of preclinical and clinical studies have shown that IDO inhibition can enhance the immune competence of the body and significantly improve the antitumor efficacy of various chemotherapeutic drugs and the efficacy against diseases caused by other immunosuppressions (c.j.d.austin and l.m.rendina, drug Discovery Today 2014,1-9). IDO-/-mouse gene knockouts are feasible and mice are healthy, meaning that IDO inhibition may not cause serious mechanism-of-action toxicity.
Small molecule inhibitors of IDO currently under development to treat and prevent the above diseases associated with IDO, for example, PCT patent application WO99/29310 discloses methods of altering T cell mediated immunity, including altering extracellular concentrations of local tryptophan and tryptophan metabolites by administering an amount of 1-methyl DL tryptophan or p- (3 benzofuranyl) -DL-alanine (Munn, 1999). WO2004/0234623 discloses compounds capable of inhibiting indoleamine 2,3-dioxygenase (IDO) activity; U.S. patent application 2004/0234623 discloses a method of treating patients with cancer or infections by administering an IDO inhibitor in combination with other treatment modalities.
In view of the large number of experimental data showing that IDO inhibitors have a good therapeutic and prophylactic effect on immunosuppression, tumor suppression, chronic infections, viral infections including HIV infection, autoimmune diseases or disorders and intra-uterine fetal rejection, etc., it is desirable to use a therapeutic approach that inhibits tryptophan degradation by inhibiting IDO activity. When T cells are inhibited by a virus such as a malignant tumor or HIV, IDO inhibitors can be used to enhance the activity of T cells. Furthermore, IDO chemistry has been studied more clearly and its x-ray crystal structure is also resolved, which helps to better exploit structure-based drug design and structural optimization of drugs. IDO is currently an attractive target for therapeutic intervention.
Disclosure of Invention
The invention aims to solve the technical problem of providing a novel five-membered heteroaromatic ring derivative, a preparation method, a pharmaceutical composition and application thereof. The five-membered heteroaromatic ring derivative has good IDO inhibition effect, and can effectively treat, relieve and/or prevent various related diseases caused by immunosuppression, such as tumors, infectious diseases, autoimmune diseases and the like.
Although the activity of the compounds of formula (I) disclosed in the present invention is shown by the inhibition of IDO, the mechanism of inhibiting IDO activity is not well studied and the possibility of inhibiting TDO (tryptophan 2,3-dioxygenase) activity is not excluded. Thus, all references to "IDO inhibitors" in the present invention can include the following meanings: IDO inhibitors, TDO inhibitors, or dual IDO and TDO inhibitors.
The invention provides a five-membered heteroaromatic ring derivative (I), an isomer, a prodrug, a stable isotope derivative or a pharmaceutically acceptable salt thereof;
wherein the ring A is pyrrole ring, and X, Y, Z is selected from the following combinations:
1) X is NR 1 Y is CR 2 And Z is CR 3 ;
2) X is CR 2 Y is NR 1 And Z is CR 3 ;
3) X is CR 3 Y is CR 2 And Z is NR 1 (ii) a Or
4) X is CR 3 Y is NR 1 And Z is CR 2 ;
Alternatively, the a ring is an imidazole ring, and X, Y, Z is selected from the group consisting of:
5) X is NR 1 Y is CR 2 And Z is N; or
6) X is N, Y is CR 2 And Z is NR 1 ;
L is CH 2 、CH(CH 3 )、C(CH 3 ) 2 Or CH 2 CH 2 ;
U and V are each independently selected from N or CR 4 ;
Cy is a benzene ring or a 5-10 membered heteroaromatic ring, said Cy is unsubstituted or further substituted by 1 to 4 groups selected from halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Alkylthio, halo C 1-6 Alkyl, halo C 1-6 Alkoxy radical, C 2-6 Alkynyl, C 2-6 Alkenyl radical, C 3-6 Cycloalkyl, -OH, -SH, -CN, -NO 2 、-OC(O)R a 、-OC(O)OR b 、-OC(O)N(R b ) 2 、-C(O)OR b 、-C(O)R a 、-C(O)N(R b ) 2 、-NR b C(O)R a 、-N(R b ) 2 、-NR b C(O)R a 、-S(O) 0-2 R a and-S (O) 2 N(R b ) 2 Is substituted at any position with one or more substituents of (a);
r is substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; when R is substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl, the substituents can be substituted as follows 1-3R is A The group is substituted at any position: -CN, -OR a 、-C(O)N(R b ) 2 、-OC(O)R a 、-OC(O)OR b 、-OC(O)N(R b ) 2 、-C(O)OR b 、-C(O)R a 、-C(O)N(R b ) 2 、-N(R b ) 2 、-NR b C(O)R a 、-NR b C(O)OR a 、-NR b C(O)N(R b ) 2 、-NR b C(O)N(R b ) 2 、-NR b S(O) 2 R a 、-NR b S(O) 2 N(R b ) 2 、-S(O) 0-2 R a 、-S(O) 2 N(R b ) 2 Halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl; r A Wherein when said alkyl, alkoxy, aryl, heteroaryl, cycloalkyl or heterocycloalkyl group is substituted, it may be further substituted by 1 to 3 groups selected from halogen, hydroxy, amino and C 1-4 Alkyl, or halo C 1-3 The substituent of the alkoxy is substituted at any position;
R 1 is H or C 1-6 An alkyl group; or, R 1 is-C (O) N (R) b ) 2 、-C(O)R a 、-C(O)OR a 、-S(O) 2 N(R b ) 2 、-S(O) 2 R a Substituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-8 Cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted 5-6 membered heteroaryl; said C is 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocycloalkyl, phenyl, or 5-6 membered heteroaryl when substituted is preferably substituted with 1 to 3 substituents selected from: deuterium, halogen, hydroxy, mercapto, amino, cyano, C 1-3 Alkyl radical, C 1-3 Alkoxy radical, C 1-3 Alkylamino radical, halogeno C 1-3 Alkoxy, halo C 1-3 Alkyl, carboxylic acid, ester group, amide group, -NH (CO) -C 1-6 Alkyl, -C (O) -C 1-6 Alkyl, -S (O) 0-2 -C 1-6 Alkyl radical, C 3-8 Cycloalkyl, or 3-8 membered heterocycloalkyl, at any position;
R 2 is substituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstituted C 3-8 Cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5-6 membered heteroaryl; when said C is 1-6 When the alkyl group is substituted, it is preferably substituted by 1 to 3 groups selected from halogen and C 1-4 Alkoxy radical, C 1-4 Alkylamino radical, halogeno C 1-4 Alkoxy, -OH, -NH 2 And one or more substituents in-CN at any position; when said C is 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl when substituted is preferably selected from 1 to 3 deuterium, halogen, C 1-4 Alkyl radical, C 1-4 Alkoxy, halo C 1-4 Alkyl, halo C 1-4 Alkoxy radical, C 1-4 Alkylamino, -OH, -NH 2 And one or more substituents in-CN at any position; or R 2 Is halogen, -CN, -OR a 、-C(O)N(R b ) 2 、-C(O)R a 、-C(O)OR a 、-S(O) 2 N(R b ) 2 、-S(O) 2 R a 、-N(R b ) 2 or-NR b C(O)R a ;
R 1 And R 2 Is independently substituted, or R 1 And R 2 Are linked to each other to form a 5-10 membered heterocycloalkyl or 5-6 membered heteroaryl; the 5-10 membered heterocycloalkyl may further comprise 1 to 3 members selected from N, O, S (O) 0-2 A heteroatom or group of C (O); the 5-10 membered heterocycloalkyl or 5-6 membered heteroaryl is unsubstituted or further substituted by 1 to 3 substituents selected from the group consisting of halogen, C 1-4 Alkyl radical, C 1-4 Alkoxy, halo C 1-4 Alkyl, halo C 1-4 Alkoxy radical, C 1-4 Alkylamino, -OH, -NH 2 And one or more substituents in-CN at any position;
R 3 is H, deuterium, halogen, cyano, amide, ester group, or C 1-3 An alkyl group;
R 4 is H, -OH, -CN, C 1-6 Alkyl, or C 1-6 An alkoxy group;
each R a And each R b Each independently selected from hydrogen, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, heterocycloalkylalkyl, cycloalkylalkyl, arylalkyl, or heteroarylalkyl, or alternatively, two R' s b Together with the N atom to which they are commonly attached form a 3-8 membered monocyclic heterocycloalkyl;
m is 1,2 or 3;
n is 0, 1 or 2.
All embodiments described below, as well as combinations of any of the embodiments, are included within the scope of the present invention as shown in formula I.
In some embodiments, the L is CH 2 。
In some embodiments, the U is CH.
In some embodiments, the V is CH.
In some embodiments, n is 1.
In some embodiments, m is 1.
In some embodiments, in the Cy, the 5-10 membered heteroaryl is 5-6 membered heteroaryl.
In some embodiments, the 5-10 membered heteroaryl in the Cy is thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, or pyridazinyl; the thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazoleThe group 1,2,5-thiadiazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, or pyridazinyl is unsubstituted or further substituted at any position with 1 to 3 substituents, the substituents being as defined above; the substituents are preferably: deuterium, halogen, amino, cyano, C 1-3 Alkyl (e.g. methyl), C 1-3 Alkoxy (e.g. methoxy, ethoxy) and halo C 1-3 Alkoxy (such as trifluoromethoxy and difluoromethoxy) is one or more.
In some embodiments, in the Cy, the 5-10 membered heteroaryl is pyridinyl, pyrimidinyl, or pyrazinyl; the pyridyl, pyrimidinyl, or pyrazinyl group is unsubstituted or further substituted at any position with 1 to 2 substituents, the substituents being as defined above; the substituents are preferably: deuterium, halogen, amino, cyano, C 1-3 Alkyl (e.g. methyl), C 1-3 Alkoxy (e.g. methoxy, ethoxy) and halo C 1-3 Alkoxy (such as trifluoromethoxy and difluoromethoxy) group.
In some embodiments, in the Cy, the 5-10 membered heteroaryl is pyridinyl; the pyridyl group is unsubstituted or further substituted at any position by 1 to 2 substituents, the substituents being as defined above; the substituents are preferably: deuterium, halogen, amino, cyano, C 1-3 Alkyl (e.g. methyl), C 1-3 Alkoxy (e.g. methoxy, ethoxy) and halo C 1-3 Alkoxy (such as trifluoromethoxy and difluoromethoxy) is one or more.
In some embodiments, the Cy is any one of the following structures: or->Wherein R is 5 And R 6 Each independently selected from H, halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Alkylthio, halogeno C 1-6 Alkyl, halo C 1-6 Alkoxy radical, C 2-6 Alkynyl, C 2-6 Alkenyl radical, C 3-6 Cycloalkyl, -OH, -SH, -CN, -NO 2 、-OC(O)R a 、-OC(O)OR b 、-OC(O)N(R b ) 2 、-C(O)OR b 、-C(O)R a 、-C(O)N(R b ) 2 、-NR b C(O)R a 、-N(R b ) 2 、-NR b C(O)R a 、-S(O) 0-2 R a or-S (O) 2 N(R b ) 2 ;R a And R b Is as defined above. Said R is 5 Preferably hydrogen, methyl, methoxy, cyano, trifluoromethoxy, ethoxy, or difluoromethoxy; the R is 6 Preferably hydrogen, deuterium, halogen, amino, cyano, C 1-3 Alkyl radical, C 1-3 Alkoxy, or halo C 1-3 An alkoxy group.
In some embodiments, the Cy is any one of the following structures:orWherein R is 5 And R 6 As defined above.
In some embodiments, the Cy is any one of the following structures:or>Wherein R is 5 And R 6 As defined above.
In some embodiments, in the Cy, the R is 5 Is H.
In some embodiments, in the Cy, the R is 5 Is methoxy, difluoromethoxy or trifluoromethoxy.
In some embodiments, in the Cy, the R is 5 Is a trifluoromethoxy group.
In some embodiments, in said R, said substituted or unsubstituted aryl is substituted or unsubstituted C 6-10 Aryl (e.g., substituted or unsubstituted phenyl or substituted or unsubstituted naphthyl).
In some embodiments, in said R, said substituted or unsubstituted heteroaryl is preferably a substituted or unsubstituted 5-to 10-membered heteroaryl group which is a substituted or unsubstituted pyridyl, substituted or unsubstituted N-pyridyloxy, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted quinolyl or substituted or unsubstituted isoquinolyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted tetrazolyl;
in some embodiments, in said R, said substituted or unsubstituted cycloalkyl is substituted or unsubstituted C 3-8 A cycloalkyl group.
In some embodiments, in said R, said substituted or unsubstituted cycloalkyl is substituted or unsubstituted C 3-8 A monocyclic cycloalkyl group.
In some embodiments, in said R, said substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 5-8 membered heterocycloalkyl.
In some embodiments, in said R, said substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 5-8 membered monocyclic heterocycloalkyl.
In some embodiments, when R is substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl, the following 1 to 3R groups can be substituted A The group is substituted at any position: -OH, -SH, -CN, -NO 2 、-NH 2 、-C(O)N(R b ) 2 、-OC(O)R a 、-OC(O)OR b 、-OC(O)N(R b ) 2 、-C(O)OR b 、-C(O)R a 、-C(O)N(R b ) 2 、-N(R b ) 2 、-NR b C(O)R a 、-NR b C(O)R a 、-NR b C(O)OR a 、-NR b C(O)N(R b ) 2 、-NR b C(O)N(R b ) 2 、-NR b S(O) 2 R a 、-NR b S(O) 2 N(R b ) 2 、-S(O) 0-2 R a 、-S(O) 2 N(R b ) 2 Halogen, alkylthio, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl.
In some embodiments, the R is A Wherein the halogen is F, cl, br, I; more preferably F or Cl.
In some embodiments, the R is A Wherein the substituted or unsubstituted alkyl is substituted or unsubstituted C 1-4 An alkyl group; more preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl.
In some embodiments, the R is A Wherein the substituted or unsubstituted alkoxy is substituted or unsubstituted C 1-4 An alkoxy group; more preferably methoxy group or ethoxy group.
In some embodiments, the R is A Wherein the substituted or unsubstituted aryl group is a substituted or unsubstituted phenyl group.
In some embodiments, the R is A The substituted or unsubstituted heteroaryl group is a substituted or unsubstituted 5-6 membered heteroaryl group.
In some embodiments, the R is A Wherein said substituted or unsubstituted cycloalkyl is substituted or unsubstituted C 3-8 A cycloalkyl group.
In some embodiments, the R is A Wherein said substituted or unsubstituted heterocycloalkyl is substituted or unsubstitutedSubstituted 5-8 membered heterocycloalkyl.
In some embodiments, the R is A Wherein said alkyl, alkoxy, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, when substituted, may be further substituted with 1 to 3 substituents selected from the group consisting of halogen, hydroxy, amino, C 1-3 Alkyl, or halo C 1-3 The substituent of the alkoxy group is substituted at an arbitrary position.
In some embodiments, the R is a And R b Each independently is hydrogen, C 1-4 Alkyl, halo C 1-3 Alkyl radical, C 3-8 Cycloalkyl, 3-8 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 3-8 membered heterocycloalkyl C 1-3 Alkyl radical, C 3-8 Cycloalkyl radical C 1-3 Alkyl, phenylalkyl, or 5-6 membered heteroaryl C 1-3 Alkyl, or, two R b Together with the N atom to which they are commonly attached form a 3-8 membered monocyclic heterocycloalkyl group.
In some embodiments, the R is a Is hydrogen, methyl, ethyl, n-propyl, or isopropyl.
In some embodiments, the R is b Is hydrogen, methyl, ethyl, n-propyl, or isopropyl.
In some embodiments, said R is substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyridinyloxy, substituted or unsubstituted quinolinyl, substituted or unsubstituted isoquinolinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted pyrrolyl; the substituted R may be represented by 1 to 3R A The group is substituted at any position: c 1-3 Alkyl (e.g. methyl, ethyl, isopropyl), C 1-3 Alkoxy (e.g. methoxy, ethoxy), F, cl, br, -OH, -NH 2 and-CN.
In some embodiments, the R is a substituted or unsubstituted phenyl, substituted or unsubstituted quinolinyl, or substituted or unsubstituted isoquinolinyl; the substituted R may be substituted at any position with 1F as follows.
In some embodiments, the R is 1 Is H.
In some embodiments, the R is 1 Is a substituted or unsubstituted methyl group, a substituted or unsubstituted ethyl group, a substituted or unsubstituted isopropyl group, or a substituted or unsubstituted cyclopropyl group. The methyl, ethyl, isopropyl or cyclopropyl group is unsubstituted or optionally substituted by 1-OH at any position.
In some embodiments, R 1 Is methyl, ethyl, isopropyl, or cyclopropyl. Said ethyl group being unsubstituted or optionally substituted at any position by 1-OH.
In some embodiments, R 1 Is H, methyl, ethyl, isopropyl, or cyclopropyl. The ethyl group is unsubstituted or optionally substituted at any position by 1-OH.
In some embodiments, the R is 2 In (1), the substituted C 1-6 Alkyl being substituted C 1-4 Alkyl, the substituent is F or-OH.
In some embodiments, the R is 2 In (1), the substituted C 1-6 Alkyl being C substituted by 1 hydroxy 1-4 An alkyl group.
In some embodiments, the R is 2 In (1), the substituted C 1-6 Alkyl is substituted methyl, the substituent preferably being-OH.
In some embodiments, the R is 2 In (1), the substituted C 1-6 Alkyl is substituted ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl; the substituent is F or-OH.
In some embodiments, the R is 2 In (1), the substituted C 1-6 The alkyl is trifluoromethyl, difluoromethyl, 2-fluoroprop-2-yl, 2,2-difluoroethyl, 1,1-difluoroethyl, hydroxymethyl (-CH) 2 OH), 2-hydroxyPhenylprop-2-yl (-C (CH) 3 ) 2 OH), or 1-hydroxy-2-methylpropan-2-yl (-C (CH) 3 ) 2 CH 2 OH)。
In some embodiments, the R is 2 In (1), the substituted C 1-6 Alkyl is hydroxymethyl (-CH) 2 OH), 2-hydroxypropan-2-yl (-C (CH) 3 ) 2 OH), or 1-hydroxy-2-methylpropan-2-yl (-C (CH) 3 ) 2 CH 2 OH)。
In some embodiments, the R is 2 In (1), the substituted or unsubstituted C 3-8 Cycloalkyl being substituted or unsubstituted C 3-6 Cycloalkyl radicals, for example: cyclopropyl, 1-methylcyclopropyl1-hydroxycyclopropyl->Cyclobutyl, cyclopentyl, cyclohexyl or 1-fluorocyclopropyl->
In some embodiments, the R is 2 Wherein said substituted or unsubstituted C 3-8 Cycloalkyl being substituted or unsubstituted C 3-6 Cycloalkyl radicals, for example: cyclopropyl, 1-methylcyclopropyl1-hydroxycyclopropyl->Cyclobutyl, cyclopentyl, or cyclohexyl.
In some embodiments, the R is 2 The substituted or unsubstituted 3-8 membered heterocycloalkyl group is a substituted or unsubstituted 3-6 membered heterocycloalkyl group, for example: 3-oxetanyl, 2-oxetanyl, 3-azetidinyl, 2-azetidinyl.
In some embodiments, the R is 2 Is halogen, C 2-4 Alkenyl, C substituted by 1 hydroxy 1-4 Alkyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl; said C is 3-6 Cycloalkyl or 3-to 6-membered heterocycloalkyl being unsubstituted or optionally substituted by 1F, -CH 3 or-OH in any position.
In some embodiments, the R is 2 Is fluorine, chlorine, trifluoromethyl, difluoromethyl, 2-fluoroprop-2-yl, 2,2-difluoroethyl, 1,1-difluoroethyl, hydroxymethyl, 1-methylcyclopropyl, 1-hydroxycyclopropyl, 1-fluorocyclopropyl, cyclobutyl, cyclopropyl, 3-oxetanyl, or 2-oxetanyl.
In some embodiments, the R is 2 Is 1-hydroxy-2-methylpropan-2-yl, 3-azetidinyl, or 2-azetidinyl.
In some embodiments, the R is 2 Is fluorine, chlorine, prop-1-en-2-yl, hydroxymethyl, 1-methylcyclopropyl, 1-hydroxycyclopropyl, cyclobutyl, cyclopropyl, 3-oxetanyl, 2-oxetanyl, 1-hydroxy-2-methylpropan-2-yl, 3-azetidinyl, or 2-azetidinyl.
In some embodiments, the R is 2 Is fluorine, chlorine, prop-1-en-2-yl, hydroxymethyl, 1-methylcyclopropyl, 1-hydroxycyclopropyl, cyclobutyl, cyclopropyl, 3-oxetanyl, 2-oxetanyl, or 1-hydroxy-2-methylprop-2-yl.
In some embodiments, the R is 3 Is H, deuterium, fluorine, chlorine, bromine, cyano, or methyl.
In some embodiments, the R is 3 Is H.
In some embodiments, the R is 4 Is H.
In some embodiments, the five-membered heteroaromatic ring derivative (I), isomer, prodrug, stable isotopic derivative or pharmaceutically acceptable salt thereof, may be defined as follows, and non-described groups may be defined as in any one of the above embodiments:
wherein the ring A is pyrrole ring, and X, Y, Z is selected from the following combinations:
1) X is NR 1 Y is CR 2 And Z is CR 3 ;
2) X is CR 2 Y is NR 1 And Z is CR 3 ;
Alternatively, the a ring is an imidazole ring, and X, Y, Z is selected from the group consisting of:
5) X is NR 1 Y is CR 2 And Z is N; or
L is CH 2 ;
U and V are each independently selected from N;
R 1 Is a substituted or unsubstituted methyl group, a substituted or unsubstituted ethyl group, a substituted or unsubstituted isopropyl group, or a substituted or unsubstituted cyclopropyl group. The methyl, ethyl, isopropyl or cyclopropyl group is unsubstituted or optionally substituted by 1-OH at any position.
R 2 Is halogen, C 2-4 Alkenyl, C substituted by 1 hydroxy 1-4 Alkyl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl; said C is 3-6 Cycloalkyl or 3-to 6-membered heterocycloalkyl being unsubstituted or optionally substituted by 1F, -CH 3 or-OH is substituted at any position;
R 3 is H;
m is 1; n is 1.
In some embodiments, the five-membered heteroaromatic ring derivative (I), isomers, prodrugs, stable isotopic derivatives, or pharmaceutically acceptable salts thereof, may be defined as follows, and non-described groups may be defined as in any one of the above embodiments:
In some embodiments, the five-membered heteroaromatic ring derivative (I), isomers, prodrugs, stable isotopic derivatives, or pharmaceutically acceptable salts thereof, may be defined as follows, and non-described groups may be defined as in any one of the above embodiments:
In some embodiments, the five-membered heteroaromatic ring derivative (I), isomer, prodrug, stable isotopic derivative or pharmaceutically acceptable salt thereof is a compound of formula (II):
wherein Cy, R 1 、R 2 And R 3 As defined above.
The following preferred embodiments are included in the definition of the compounds represented by formula (II):
In some preferred embodiments, R 1 Is H.
In some preferred embodiments, R 1 Is methyl, or hydroxyethyl.
In some preferred embodiments, R 1 Is H or methyl.
In some preferred embodiments, R 2 Is hydroxymethyl, prop-1-en-2-yl, 1-methylcyclopropyl, 1-hydroxycyclopropyl, cyclobutyl, cyclopropyl, 3-oxetanyl, 2-oxetanyl, 1-hydroxy-2-methylpropan-2-yl, 3-azetidinyl, or 2-azetidinyl.
In some preferred embodiments, R 3 Is H or D.
In some preferred embodiments, R 3 Is H.
In some embodiments, the five-membered heteroaromatic ring derivative (I), isomer, prodrug, stable isotopic derivative or pharmaceutically acceptable salt thereof is a compound of formula (III):
wherein, Cy、R、R 1 、R 2 And R 3 As defined above.
The following preferred embodiments are included in the definition of the compounds represented by formula (III):
In some preferred embodiments, R 1 Is H.
In some preferred embodiments, R 1 Is methyl.
In some preferred embodiments, R 2 Substituted F, cl, hydroxymethyl.
In some preferred embodiments, R 3 Is H or D.
In some preferred embodiments, R 3 Is H.
In some embodiments, the five-membered heteroaromatic ring derivative (I), isomer, prodrug, stable isotopic derivative or pharmaceutically acceptable salt thereof is a compound of formula (IV):
wherein Cy, R 1 、R 2 And R 3 As defined above.
The following preferred embodiments are included in the definition of the compounds represented by formula (IV):
In some preferred embodiments, R 1 Is H.
In some preferred embodiments, R 2 Is cyclopropyl or cyclobutyl.
In some embodiments, the five-membered heteroaromatic ring derivative (I), isomer, prodrug, stable isotopic derivative or pharmaceutically acceptable salt thereof is a compound of formula (V) or (VI):
wherein X, Y, Z, cy, L and R are as defined above.
The following preferred embodiments are included in the definition of the compounds represented by the formula (V) or (VI):
in some preferred embodiments, L is CH 2 。
In some embodiments, the five-membered heteroaromatic ring derivative (I), isomers, prodrugs, stable isotopic derivatives, or pharmaceutically acceptable salts thereof, may be defined as follows, and non-described groups may be defined as in any one of the above embodiments:
wherein ring a is a pyrrole ring and X, Y, Z is selected from the group consisting of:
1) X is NR 1 Y is CR 2 And Z is CR 3 ;
2) X is CR 2 Y is NR 1 And Z is CR 3 ;
3) X is CR 3 Y is CR 2 And Z is NR 1 (ii) a Or
4) X is CR 3 Y is NR 1 And Z is CR 2 ;
L is CH 2 、CH(CH 3 )、C(CH 3 ) 2 Or CH 2 CH 2 ;
U and V are each independently selected from N or CR 4 ;
Cy is a benzene ring or a 5-10 membered heteroaromatic ring, said Cy is unsubstituted or further substituted by 1 to 4 groups selected from halogen, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Alkylthio, halo C 1-6 Alkyl, halo C 1-6 Alkoxy radical, C 2-6 Alkynyl, C 2-6 Alkenyl radical, C 3-6 Cycloalkyl, -OH, -SH, -CN, -NO 2 、-OC(O)R a 、-OC(O)OR b 、-OC(O)N(R b ) 2 、-C(O)OR b 、-C(O)R a 、-C(O)N(R b ) 2 、-NR b C(O)R a 、-N(R b ) 2 、-NR b C(O)R a 、-S(O) 0-2 R a and-S (O) 2 N(R b ) 2 Is substituted at any position with one or more substituents of (a);
r is cycloalkyl, heterocycloalkyl, aryl or heteroaryl; said R is unsubstituted or further substituted by 1 to 3R A The group is substituted at any position: -CN, -OR a 、-C(O)N(R b ) 2 、-OC(O)R a 、-OC(O)OR b 、-OC(O)N(R b ) 2 、-C(O)OR b 、-C(O)R a 、-C(O)N(R b ) 2 、-N(R b ) 2 、-NR b C(O)R a 、-NR b C(O)R a 、-NR b C(O)OR a 、-NR b C(O)N(R b ) 2 、-NR b C(O)N(R b ) 2 、-NR b S(O) 2 R a 、-NR b S(O) 2 N(R b ) 2 、-S(O) 0-2 R a 、-S(O) 2 N(R b ) 2 Halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl; r is A Wherein when said alkyl, alkoxy, aryl, heteroaryl, cycloalkyl or heterocycloalkyl group is substituted, it may be further substituted by 1 to 3 groups selected from halogen, hydroxy, amino and C 1-4 Alkyl, or halo C 1-3 The substituent of the alkoxy is substituted at any position;
R 1 is H or C 1-6 An alkyl group;
R 2 is substituted C 1-6 Alkyl, substituted or unsubstituted C 2-6 Alkenyl, substituted or unsubstituted C 2-6 Alkynyl, substituted or unsubstitutedC 3-8 Cycloalkyl, or substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5-6 membered heteroaryl; when said C is 1-6 The alkyl group is optionally substituted by 1 to 3 groups selected from halogen, C 1-4 Alkoxy, halo C 1-4 Alkoxy, -OH, -NH 2 And one or more substituents in-CN at any position; when said C is 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl optionally substituted with 1 to 3 substituents selected from deuterium, halogen, C 1-4 Alkyl radical, C 1-4 Alkoxy, halo C 1-4 Alkyl, halo C 1-4 Alkoxy, -OH, -NH 2 And one or more substituents in-CN at any position;
R 3 is H, deuterium, halogen, cyano, amide, ester group, or C 1-3 An alkyl group;
R 4 is H, -OH, -CN, C 1-6 Alkyl, or C 1-6 An alkoxy group;
each R a And each R b Each independently selected from hydrogen, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, heterocycloalkylalkyl, cycloalkylalkyl, arylalkyl, or heteroarylalkyl, or alternatively, two R' s b Together with the N atom to which they are both attached form a 3-8 membered monocyclic heterocycloalkyl;
m is 1,2 or 3;
n is 0, 1 or 2.
In some embodiments, the five-membered heteroaromatic ring derivative (I), isomer, prodrug, stable isotopic derivative or pharmaceutically acceptable salt thereof is any one of the following structures:
in some embodiments, the five-membered heteroaromatic ring derivative (I), isomer, prodrug, stable isotopic derivative, or pharmaceutically acceptable salt thereof is any one of the following structures:
in some embodiments, the five-membered heteroaromatic ring derivative (I), isomer, prodrug, stable isotopic derivative or pharmaceutically acceptable salt thereof is any one of the following structures:
in some embodiments, the five-membered heteroaromatic ring derivative (I), isomer, prodrug, stable isotopic derivative or pharmaceutically acceptable salt thereof is any one of the following structures:
the invention also provides a preparation method of the five-membered heteroaromatic ring derivative (I), an isomer, a prodrug, a stable isotope derivative or a pharmaceutically acceptable salt thereof, which is any one of the following methods.
The method comprises the following steps: in a solvent, carrying out condensation reaction on a compound I-b and a compound X-1 under the action of alkali;
wherein Cy, X, Y, Z, L, R, U, V, m and n are as defined above.
In the method shown in the reaction formula 1, the conditions and steps of the condensation reaction may be those conventional in the art, and the following reaction conditions are particularly preferred in the present invention: the solvent is preferably dichloromethane or N, N-dimethylformamide; the dosage of the solvent is preferably 5-20 mL/mmol of the compound I-b; the alkali is preferably N, N-diisopropylethylamine, N-methylmorpholine or triethylamine; the molar ratio of the alkali to the compound I-b is preferably 1:1-5:1; in order to accelerate the reaction speed, a catalytic amount of 4-dimethylaminopyridine can be added into the reaction system, and the molar ratio of the 4-dimethylaminopyridine to the compound I-b is preferably 0.05. The condensing agent in the condensation reaction is preferably 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), dicyclohexylcarbodiimide (DCC) or N, N' -Diisopropylcarbodiimide (DIC), more preferably EDCI, and the molar ratio of the condensing agent to the compound I-b is preferably 1:1-3:1; the reaction temperature is preferably 0-30 ℃; the reaction can be detected by TLC, and the end point of the reaction is generally the time when the compound I-b disappears, preferably 0.5 to 24 hours; after the reaction is finished, the product can be further purified by post-treatment, and the method preferably comprises the following steps: after quenching the reaction system with ice water, diluting with a solvent, separating the organic phase, drying the organic phase, removing the organic solvent under reduced pressure, and purifying the residue by a conventional purification means such as silica gel column chromatography, flash column chromatography or prep-HPLC. The steps and conditions for silica gel column chromatography, flash column chromatography or prep-HPLC purification may be those conventionally used in the art.
The preparation of said compounds I-b may be conventional in the art for such reactions, preferably comprising the steps of: in a solvent, carrying out deprotection reaction on the compound I-a;
wherein Pg is a carboxyl protecting group, preferably C 1-6 Alkyl, more preferably methyl or ethyl; cy, X, Y and Z are as defined above.
In the process shown in the reaction formula 2, the deprotection reaction of the compound I-a can be carried out under acidic conditions or basic conditions. The acidic conditions are preferably a hydrochloric acid/alcohol system, or a hydrogen chloride/alcohol system, the alcohol preferably being methanol or ethanol. In alkaline conditions: the solvent can be a solvent commonly used in the reaction in the field, preferably ethanol, methanol, tetrahydrofuran, water, or a mixed solvent of any 2 to 4 of ethanol, methanol, tetrahydrofuran and water, more preferably an ethanol/water mixed solvent, wherein the volume ratio of the ethanol to the water is preferably 1. The amount of the solvent does not generally affect the reaction, and is preferably 5 to 15mL/mmol of the compound I-a. The alkali is preferably sodium hydroxide, potassium hydroxide or lithium hydroxide, more preferably sodium hydroxide, the molar ratio of the alkali to the compound I-a is preferably 2:1-10, and the alkali can be usually dissolved in water in a mixture solvent to prepare an aqueous solution of the alkali. The temperature of the deprotection reaction is preferably 20 to 100 ℃, more preferably 60 to 100 ℃, and still more preferably 80 to 100 ℃. The progress of the reaction can be checked by TLC, and it is generally preferable that the end point of the reaction is 10 minutes to 2 hours, when the compound I-a disappears. After the reaction is finished, the product can be further purified by post-treatment, and the method preferably comprises the following steps: concentrating under reduced pressure to remove organic solvent, acidifying residue, filtering the obtained solid, and vacuum drying the filter cake to obtain compound I-b.
The second method comprises the following steps: in a solvent, under the action of trimethylaluminum, carrying out amine ester exchange reaction on a compound I-a and a compound X-1;
wherein Pg is a carboxyl protecting group, preferably C 1-6 Alkyl, more preferably methyl or ethyl; cy, X, Y, U, V, m, n, Z, L and R are as defined above.
In the process shown in the reaction formula 3, the conditions and steps of the condensation reaction may be those of amine transesterification reaction which is conventional in the art, and the following reaction conditions are particularly preferred in the present invention: the solvent is preferably toluene, and the dosage of the solvent is preferably 5-20 mL/mmol of the compound I-a; the molar ratio of trimethylaluminum to the compound X-1 is preferably 2:1 to 3:1. The molar ratio of the compound X-1 to the compound I-a is preferably 1:1-3:1; the reaction temperature is preferably between room temperature and solvent reflux; the reaction temperature is more preferably 90-110 ℃; the reaction can be detected by TLC, and the end point of the reaction is generally determined as the disappearance of the compound I-a, preferably 1 to 24 hours; after the reaction is finished, the product can be further purified through post-treatment, and the purification method comprises silica gel column chromatography, flash column chromatography or prep-HPLC purification. The steps and conditions for silica gel column chromatography, flash column chromatography or prep-HPLC purification may be those conventionally used in the art.
The compound I-a can be synthesized by the method shown in the reaction formulas 4 to 6:
wherein Pg is a carboxyl protecting group, preferably C 1-6 Alkyl, more preferably methyl or ethyl; x is iodine, bromine or chlorine; cy, R 1 And R 2 Is as defined above.
Wherein Pg is a carboxyl protecting group, preferably C 1-6 Alkyl, more preferably methyl, ethyl or tert-butyl; r 2 Is Cl or Br; cy is as defined above.
Wherein Pg is a carboxyl protecting group, preferably C 1-6 Alkyl, more preferably methyl or ethyl; cy and R 2 Is as defined above.
Wherein Pg is a carboxyl protecting group, preferably C 1-6 Alkyl, more preferably methyl or ethyl; cy and R 2 Is as defined above.
In the above reaction formulae 1 to 7, when an amino group, a hydroxyl group or a carboxyl group which does not participate in the reaction is present, the amino group, the hydroxyl group or the carboxyl group is preferably protected by a protecting group to avoid any side reaction. If the amino protecting group or the hydroxyl protecting group exists, the compound shown as the formula I is obtained after subsequent deprotection steps. Any suitable amino protecting group, for example: a tert-butyloxycarbonyl (Boc) group, both of which can be used to protect the amino group. If Boc is used as the protecting group, the subsequent deprotection reaction can be carried out under standard conditions, for example, in a p-toluenesulfonic acid/methanol system, a dichloromethane/trifluoroacetic acid system, a saturated ethereal hydrogen chloride solution, or trimethylsilyl trifluoromethanesulfonate/2,6-lutidine/dichloromethane system; any suitable hydroxyl protecting group, for example: tert-butyldimethylsilyl groups, all of which can be used to protect hydroxyl groups, and subsequent deprotection reactions can be carried out under standard conditions, for example, in the sodium hydroxide/methanol/water system; any suitable carboxyl protecting group, for example: the formation of carboxylate groups (e.g., methyl carboxylate, ethyl carboxylate) can all be used to protect carboxyl groups, and subsequent deprotection reactions can be performed under standard conditions, e.g., sodium hydroxide, potassium hydroxide, lithium hydroxide in tetrahydrofuran, water, and/or methanol solvents.
The pharmaceutically acceptable salt of the five-membered heteroaromatic ring derivative (I) can be synthesized by a general chemical method.
In general, salts can be prepared by reacting the free base or acid with a stoichiometric equivalent or excess of the acid (inorganic or organic) or base (inorganic or organic) in a suitable solvent or solvent composition.
The invention also provides a pharmaceutical composition, which comprises a therapeutically effective amount of active components and pharmaceutically acceptable auxiliary materials; the active component comprises one or more of five-membered heteroaromatic ring derivatives (I), isomers, prodrugs, stable isotope derivatives and pharmaceutically acceptable salts thereof.
In the pharmaceutical composition, the active ingredient may also include other therapeutic agents for cancer, viral infections or autoimmune diseases.
In the pharmaceutical composition, the pharmaceutically acceptable adjuvant may include a pharmaceutically acceptable carrier, diluent and/or excipient.
The pharmaceutical composition may be formulated into various types of administration unit dosage forms, such as tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, injections (solutions and suspensions), and the like, preferably liquids, suspensions, emulsions, suppositories, injections (solutions and suspensions), and the like, according to the therapeutic purpose.
For shaping the pharmaceutical composition in the form of tablets, any excipient known and widely used in the art may be used. For example, carriers such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid, and the like; binders such as water, ethanol, propanol, common syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose and potassium phosphate, polyvinylpyrrolidone, etc.; disintegrators such as dry starch, sodium alginate, agar powder and kelp powder, sodium bicarbonate, calcium carbonate, fatty acid esters of polyethylene sorbitan, sodium lauryl sulfate, monoglyceride stearate, starch, lactose and the like; disintegration inhibitors such as white sugar, glycerol tristearate, coconut oil and hydrogenated oil; adsorption promoters such as quaternary ammonium hydroxide and sodium lauryl sulfate; humectants such as glycerin, starch, and the like; adsorbents such as starch, lactose, kaolin, bentonite, and colloidal silicic acid; and lubricants such as pure talc, stearates, boric acid powder, polyethylene glycol, and the like. Optionally, conventional coating materials can be selected to make into sugar-coated tablet, gelatin film-coated tablet, enteric coated tablet, film-coated tablet, double-layer film tablet and multilayer tablet.
For shaping the pharmaceutical composition in the form of pellets, any of the excipients known and widely used in the art may be used, for example, carriers such as lactose, starch, coconut oil, hardened vegetable oil, kaolin, talc and the like; binders such as gum arabic powder, tragacanth powder, gelatin, ethanol and the like; disintegrating agents, such as agar and kelp powder.
For shaping the pharmaceutical composition in the form of suppositories, any excipient known and widely used in the art may be used, for example, polyethylene glycol, coconut oil, higher alcohols, esters of higher alcohols, gelatin, semisynthetic glycerides and the like.
For preparing the pharmaceutical composition in the form of injection, the solution or suspension can be sterilized (preferably, appropriate amount of sodium chloride, glucose or glycerol, etc.) to make into injection with blood isotonic pressure. In the preparation of ampoules, any of the carriers commonly used in the art may also be used. For example, water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, and fatty acid esters of polyethylene sorbitan, and the like. In addition, conventional lytic agents, buffers, analgesics, and the like may be added.
In the present invention, the content of the composition in the pharmaceutical composition is not particularly limited, and can be selected from a wide range, and usually 5 to 95% by mass, preferably 30 to 80% by mass.
In the present invention, the method of administration of the pharmaceutical composition is not particularly limited. The formulation of various dosage forms can be selected for administration according to the age, sex and other conditions and symptoms of the patient. For example, tablets, pills, solutions, suspensions, emulsions, granules or capsules are administered orally; the injection can be administered alone or mixed with injectable delivery solution (such as glucose solution and amino acid solution) for intravenous injection; suppositories are administered rectally.
The invention also provides the five-membered heteroaromatic ring derivative (I), an isomer, a prodrug, a stable isotope derivative or a pharmaceutically acceptable salt thereof, or an application of the pharmaceutical composition in preparation of indoleamine 2,3-dioxygenase inhibitor. The indoleamine 2,3-dioxygenase inhibitor (IDO 1 inhibitor) is a compound which can inhibit IDO1 activity or expression (including abnormal activity or overexpression of IDO 1) and reverse IDO 1-mediated immunosuppression. The IDO1 inhibitor can inhibit IDO1.
The invention also provides the five-membered heteroaromatic ring derivative (I), an isomer, a prodrug, a stable isotope derivative or a pharmaceutically acceptable salt thereof, or an application of the pharmaceutical composition in preparing a medicament for stimulating T cell proliferation.
The use of the five-membered heteroaromatic ring derivative of formula (I) and/or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any embodiment of the invention, for the manufacture of a medicament for the treatment, alleviation and/or prevention of a related disorder mediated by IDO1, comprising administering to the individual (e.g. patient) a therapeutically required amount of a compound or pharmaceutical composition of the invention. By IDO1 mediated related disease is meant any disease, condition or disorder that can be treated, ameliorated and/or prevented with an IDO1 inhibitor. In particular said diseases caused by IDO1 mediated immunosuppression, said diseases including but not limited to: viral, or other infections (e.g., skin infections, gastrointestinal tract infections, urogenital infections, systemic infections, etc.), cancer, or autoimmune diseases (e.g., rheumatoid arthritis, lupus erythematosus, psoriasis, etc.).
The invention also provides the application of the five-membered heteroaromatic ring derivative (I), the isomer, the prodrug, the stable isotope derivative or the pharmaceutically acceptable salt thereof or the pharmaceutical composition in preparing medicines for treating, relieving and/or preventing related diseases mediated by indoleamine 2,3-dioxygenase. The five-membered heteroaromatic ring derivatives (I), isomers, prodrugs, solvates, hydrates, stable isotopic derivatives or pharmaceutically acceptable salts thereof, or the pharmaceutical compositions may also be used in combination with one or more other types of therapeutic agents and/or methods for the treatment of cancer for the treatment, alleviation and/or prevention of related disorders mediated by indoleamine 2,3-dioxygenase. The 2,3-dioxygenase mediated related diseases refer to diseases caused by 2,3-dioxygenase mediated immunosuppression, and the diseases can comprise: viral, or other infections (e.g., skin infections, gastrointestinal tract infections, urogenital infections, systemic infections, etc.), cancer, or autoimmune diseases (e.g., rheumatoid arthritis, lupus erythematosus, psoriasis, etc.).
The other therapeutic agents for treating cancer may be administered in a single dosage form with the five-membered heteroaromatic ring derivative (I) or in separate sequential dosage forms.
Such other classes of therapeutic agents and/or methods of treatment for treating cancer may include, but are not limited to: one or more of tubulin inhibitors, alkylating agents, topoisomerase I/II inhibitors, platinum-based compounds, antimetabolites, hormones and hormone analogs, signal transduction pathway inhibitors, angiogenesis inhibitors, targeted therapies (e.g., specific kinase inhibitors), immunotherapeutic agents, pro-apoptotic agents, cell cycle signaling pathway inhibitors, and radiation therapy.
The tubulin inhibitor may be selected from, but not limited to: vinblastine series (e.g., vinblastine, vincristine, vinorelbine, vindesine), taxanes (docetaxel, paclitaxel) and methanesulfonic acid Ai Ribu forest.
The alkylating agent may be selected from, but not limited to: nitrogen mustards, ethylene imine derivatives, methane sulfonates, nitrosoureas, and triazenes.
The topoisomerase I/II inhibitor may be selected from, but is not limited to: one or more of irinotecan, topotecan, doxorubicin and dexrazoxane.
The platinum-based compound may be selected from, but is not limited to: cisplatin and/or carboplatin.
The antimetabolite may be selected from, but not limited to: folic acid antagonists, pyrimidine analogs, purine analogs, adenosine deaminase inhibitors, such as: one or more of methotrexate, 5-fluorouracil, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatin and gemcitabine.
The immunotherapeutic agent may be selected from, but is not limited to: anti-tumor vaccines (e.g., synthetic peptides, DNA vaccines, and recombinant viruses), oncolytic viruses, immunostimulatory antibodies, novel adjuvants, cytokine therapy (e.g., IL2 and GM-CSF), chimeric antigen receptor T-cell therapy (CAR-T), small molecule immunomodulators, tumor microenvironment modulators, and anti-angiogenic factors. The immunostimulatory antibodies may include, but are not limited to: 1) Protein antagonists that inhibit T cell activity (e.g.: immune checkpoint inhibitors): CTLA4 (e.g., ipilimumab and tremelimumab), PD-1 (e.g., pembrolizumab and nivolumab), PD-L1 (e.g., durvalumab, avelumab, and atezolizumab), PD-L2, LAG3, TIM1, TIM3, TIM4, CD73, galectin9, CEACAM-1, BTLA, CD69, galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, and LAIR 1; 2) Protein agonists that stimulate T cell activity: one or more of B7-1, B7-2, CD28, ICOS-L, GITR, GITRL, CD70, DR3, CD28H, GITR, OX40L, 4-1BB (CD 137), CD27, and CD 40. 3) Receptor antagonists acting on NK cells: KIR (e.g., iilumab); 4) Receptor antagonists that inhibit or deplete macrophages or monocytes: CSF-1R.
The signal transduction pathway inhibitor (STI) may be selected from, but is not limited to: BCR/ABL kinase inhibitors, epidermal growth factor receptor inhibitors, her-2/neu receptor inhibitors, AKT family kinase inhibitors, PI3K signaling pathway inhibitors, and cell cycle checkpoint inhibitors.
The angiogenesis inhibitor may be selected from, but not limited to: one or more of a VEGF/VEGFR signaling pathway inhibitor, a Src family kinase inhibitor, a Src signaling pathway inhibitor, and a c-Fes kinase inhibitor.
The viral infection may include: infections caused by viruses such as influenza, hepatitis B Virus (HBV), hepatitis C Virus (HCV), human Papilloma Virus (HPV), cytomegalovirus (CMV), epstein-barr virus (EBV), poliovirus, varicella-zoster virus, coxsackie virus, or Human Immunodeficiency Virus (HIV).
The cancer may comprise a solid tumor or a liquid tumor.
In some embodiments, the solid tumor can include, but is not limited to, related tumors of the eye, bone, lung, stomach, pancreas, breast, prostate, brain (including glioblastomas and medulloblastomas), ovary (including those stromal, germ, and stromal cells produced from epithelial cells), bladder, testis, spinal cord, kidney (including adenocarcinomas, wilms), mouth, lip, throat, oral cavity (including squamous cell carcinoma), nasal cavity, small intestine, colon, rectum, parathyroid, gallbladder, bile duct, cervix, heart, hypopharynx, bronchus, liver, ureter, vagina, anus, laryngeal gland, thyroid (including thyroid and medullary carcinoma), esophagus, nasopharyngeal pituitary, salivary gland, adrenal gland, head and neck intraepithelial neoplasia (including Bowen's disease and Paget's disease), sarcoma (including leiomyosarcoma, rhabdomyosarcoma, fibrosarcoma, osteosarcoma), skin (including melanoma, kaposi's sarcoma, solvacel cancer, and squamous cell carcinoma), and the like.
In some embodiments, the liquid tumor can include, but is not limited to, tumors associated with lymphoid tissues (including acute lymphocytic leukemia, lymphoma, myeloma, chronic lymphocytic leukemia, hodgkin's disease, non-hodgkin's lymphoma and lymphocytic lymphoma, T-cell and B-cell chronic lymphocytic leukemia), chronic lymphocytic leukemia, myeloid leukemia and aids-related leukemia.
In some embodiments, the autoimmune disease may include, but is not limited to: rheumatoid arthritis, systemic lupus erythematosus, mixed Connective Tissue Disease (MCTD), systemic scleroderma (including CREST syndrome), dermatomyositis, nodular vasculitis, nephropathy (including hemorrhagic nephritis syndrome, acute glomerulonephritis, primary membranous proliferative glomerulonephritis, etc.), endocrine-related diseases (including type I diabetes, gonadal insufficiency, pernicious anemia, hyperthyroidism, etc.), liver diseases (including primary biliary cirrhosis, autoimmune cholangitis, autoimmune hepatitis, primary sclerosing cholangitis, etc.), and autoimmune reactions due to infection (e.g., AIDS, malaria, etc.).
The invention also provides a method for inhibiting the degradation of tryptophan in a system by using the five-membered heteroaromatic ring derivative (I), an isomer, a prodrug, a stable isotope derivative or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition, which comprises the following steps: inhibiting degradation of tryptophan in a mammal by administering to the mammal a therapeutically effective amount of a compound of formula (I); the system is tissues, mammals or cell tissues expressing IDO.
The mammal, preferably a human.
In the present invention, when the bond to a substituent exhibits an intersection with a bond linking two atoms in the ring, then such substituent may be bonded to any bondable ring atom on the ring.
Unless otherwise indicated, the following terms appearing in the specification and claims of the invention have the following meanings:
the term "alkyl" refers to a saturated straight or branched chain hydrocarbon group containing 1 to 20 carbon atoms, preferably 1 to 8 carbon atoms, more preferably 1 to 6,1 to 5, 1 to 4,1 to 3, or 1 to 2 carbon atoms, representative examples of alkyl groups including but not limited to: methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, isobutyl, pentyl, hexyl, heptyl, 4,4-dimethylpentyl, 2,2,4-trimethylpentyl, and their various isomers, and the like.
The term "cycloalkyl" refers to a saturated or partially unsaturated (containing 1 or 2 double bonds) monocyclic or polycyclic group containing 3 to 20 carbon atoms. "monocyclic cycloalkyl" is preferably 3-10 membered monocyclic cycloalkyl, more preferably 3-8 membered monocyclic cycloalkyl, more preferably 3-6 membered monocyclic cycloalkyl, for example: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, cyclohexenyl. "polycyclic cycloalkyl" includes "fused cycloalkyl" and "spirocycloalkyl," fused cycloalkyl "comprising a monocyclic cycloalkyl ring fused to an aryl, cycloalkyl, or heteroaryl, and fused bicyclic cycloalkyl including, but not limited to: benzocyclobutene, 2,3-dihydro-1-H-indene, 2,3-cyclopentenopyridine, 5,6-dihydro-4H-cyclopentyl [ B ] thiophene, decahydronaphthalene and the like. "spirocycloalkyl" refers to a bicyclic group formed by two cycloalkyl groups sharing a common carbon atom, and includes, but is not limited to: spiro [2.4] heptyl, spiro [4.5] decane, and the like. The monocyclic cycloalkyl or bicyclic cycloalkyl can be linked to the parent molecule through any carbon atom in the ring.
The term "heterocycloalkyl" refers to a saturated or partially unsaturated (containing 1 or 2 double bonds) 3-to 20-membered non-aromatic cyclic group consisting of carbon atoms and heteroatoms selected from nitrogen, oxygen or sulfur, which cyclic group may be a monocyclic or bicyclic group, in the present invention, the number of heteroatoms in the heterocycloalkyl is preferably 1,2,3 or 4, and the nitrogen, carbon or sulfur atoms in the heterocycloalkyl may be optionally oxidized. The nitrogen atom may optionally be further substituted with other groups to form tertiary amines or quaternary ammonium salts. "monocyclic heterocycloalkyl" is preferably 3-to 10-membered monocyclic heterocycloalkyl, more preferably 5-to 8-membered monocyclic heterocycloalkyl. For example: aziridinyl, tetrahydrofuran-2-yl, morpholin-4-yl, thiomorpholin-S-oxide-4-yl, piperidin-1-yl, N-alkylpiperidin-4-yl, pyrrolidin-1-yl, N-alkylpyrrolidin-2-yl, piperazin-1-yl, 4-alkylpiperazin-1-yl, and the like. "polycyclic heterocycloalkyl" includes "fused heterocycloalkyl" and "spiroheterocyclyl". "fused heterocycloalkyl" includes a monocyclic heterocycloalkyl ring fused to a phenyl, heterocycloalkyl, cycloalkyl or heteroaryl group, including, but not limited to: 2,3-dihydrobenzofuranyl, 1,3-dihydroisobenzofuranyl, indolinyl, 2,3-dihydrobenzo [ b ] thienyl, dihydrobenzopyranyl, and 1,2,3,4-tetrahydroquinolinyl, and the like. "spiroheterocyclyl" refers to a bicyclic group formed by two heterocycloalkyl groups or one cycloalkyl group and one heterocycloalkyl group sharing a carbon atom. Monocyclic heterocycloalkyl and polycyclic heterocycloalkyl can be linked to the parent molecule through any ring atom in the ring. The above ring atoms particularly denote carbon atoms and/or nitrogen atoms constituting the ring skeleton.
The term "cycloalkylalkyl" refers to a cycloalkyl group attached to the parent nuclear structure through an alkyl group. Thus, "cycloalkylalkyl" encompasses the definitions of alkyl and cycloalkyl above.
The term "heterocycloalkylalkyl" refers to a linkage between a heterocycloalkyi and the parent core structure through an alkyl group. Thus, "heterocycloalkylalkyl" embraces the definitions of alkyl and heterocycloalkyl described above.
The term "alkoxy" refers to a cyclic or acyclic alkyl group having the indicated number of carbon atoms attached through an oxygen bridge, including alkyloxy, cycloalkyloxy, and heterocycloalkyloxy. Thus, "alkoxy" encompasses the above definitions of alkyl, heterocycloalkyl, and cycloalkyl.
The term "alkylthio" means a cyclic or acyclic alkyl group interconnected through the sulfur atom and the parent molecule, and includes alkylmercapto, cycloalkylmercapto, and heterocycloalkylmercapto. Thus, "alkylthio" encompasses the definitions of alkyl, heterocycloalkyl, and cycloalkyl above.
The term "alkenyl" refers to a straight, branched, or cyclic non-aromatic hydrocarbon group containing at least 1 carbon-carbon double bond. Wherein 1-3 carbon-carbon double bonds, preferably 1 carbon-carbon double bond, may be present. The term "C 2-4 Alkenyl "means an alkenyl group having 2 to 4 carbon atoms, the term" C 2-6 Alkenyl "means alkenyl having 2 to 6 carbon atoms and includes ethenyl, propenyl, butenyl, 2-methylbutenyl and cyclohexenyl.
The term "alkynyl" refers to a straight, branched, or cyclic hydrocarbon group containing at least 1 carbon-carbon triple bond. Wherein 1-3 carbon-carbon triple bonds may be present, preferably 1 carbon-carbon triple bond is present. The term "C 2-6 Alkynyl "refers to alkynyl groups having 2 to 6 carbon atoms and includes ethynyl, propynyl, butynyl, and 3-methylbutynyl.
The term "aryl" refers to any stable 6-10 membered monocyclic or bicyclic aromatic group, for example: phenyl, naphthyl, tetrahydronaphthyl, 2,3-indanyl, biphenyl, or the like.
The term "heteroaryl" refers to an aromatic ring group formed by replacement of at least 1 ring carbon atom with a heteroatom selected from N, O or S, wherein the N atom may be further oxidized. The heteroaryl group may be a 5-7 membered monocyclic ring structure or a 7-12 membered bicyclic ring structure, preferably a 5-10 membered heteroaryl group, more preferably a 5-6 membered heteroaryl ring. In the present invention, the number of heteroatoms is preferably 1,2 or 3, including but not limited to: pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyridazin-3 (2H) -onyl, furyl, thienyl, thiazolyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, triazolyl (1,2,4-triazolyl, 1,2,3-triazolyl), tetrazolyl, indazolyl, isoindolyl, benzofuranyl, benzothienyl, benzo [ d ] [1,3] dioxolanyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, and the like.
The term "arylalkyl" refers to an aryl group attached to the parent core structure through an alkyl group. Thus, "arylalkyl" encompasses the above definitions of alkyl and aryl groups.
The term "heteroarylalkyl" refers to a heterocycloalkyl group attached to the parent nucleus structure through an alkyl group. Thus, "heteroarylalkyl" embraces the definitions of alkyl and heteroaryl as described above.
The term "halogen" denotes fluorine, chlorine, bromine or iodine.
The term "haloalkyl" refers to an alkyl group optionally substituted with a halogen. Thus, "haloalkyl" encompasses the above definitions of halogen and alkyl.
The term "haloalkoxy" refers to an alkoxy group optionally substituted with a halogen. Thus, "haloalkoxy" encompasses the above definitions of halogen and alkoxy.
The term "cyano" refers to — CN.
The term "amino" refers to the group-NH 2 . The term "alkylamino" refers to an amino group wherein at least one hydrogen atom is replaced with an alkyl group, including, but not limited to: -NHCH 3 、-N(CH 3 ) 2 、-NHCH 2 CH 3 、-N(CH 2 CH 3 ) 2 。
The term "amido" refers to-C (O) N (R') 2 Wherein each R' is independently hydrogen or C 1-6 An alkyl group.
The term "ester group" refers to-C (O) OR ', wherein each R' is independently hydrogen OR C 1-6 An alkyl group.
The isotopically substituted derivatives include: an isotopically substituted derivative in which any hydrogen atom in formula I is substituted with 1 to 5 deuterium atoms, an isotopically substituted derivative in which any carbon atom in formula I is substituted with 1 to 3 carbon 14 atoms, or an isotopically substituted derivative in which any oxygen atom in formula I is substituted with 1 to 3 oxygen 18 atoms.
By "prodrug" is meant a compound that is metabolized in vivo to the original active compound. Prodrugs are typically inactive substances or less active than the active parent compound, but may provide convenient handling, administration, or improved metabolic properties.
The "Pharmaceutically acceptable salts" of the present invention are discussed in Berge, et al, "pharmaceutical acceptable salts", j.pharm.sci.,66,1-19 (1977), and are readily apparent to the pharmaceutical chemist, are substantially non-toxic and provide the desired pharmacokinetic properties, palatability, absorption, distribution, metabolism or excretion, etc. The compounds of the present invention may have an acidic group, a basic group or an amphoteric group, and typical pharmaceutically acceptable salts include salts prepared by reacting the compounds of the present invention with an acid, for example: hydrochloride, hydrobromide, sulphate, pyrosulphate, hydrogen sulphate, sulphite, bisulphite, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, nitrate, acetate, propionate, decanoate, octanoate, formate, acrylate, isobutyrate, hexanoate, heptanoate, oxalate, malonate, succinate, suberate, benzoate, methylbenzoate, phthalate, maleate, methanesulfonate, p-toluenesulfonate, (D, L) -tartaric acid, citric acid, maleic acid, (D, L) -malic acid, fumaric acid, succinic acid, succinate, lactate, trifluoromethanesulfonate, naphthalene-1-sulfonate, mandelate, pyruvate, stearate, ascorbate, salicylate. When the compound of the present invention contains an acidic group, pharmaceutically acceptable salts thereof may further include: alkali metal salts, such as sodium or potassium salts; alkaline earth metal salts, such as calcium or magnesium salts; examples of the organic base salt include salts with ammonia, alkylamines, hydroxyalkylamines, amino acids (lysine and arginine), and N-methylglucamine.
The term "isomers" as used herein means that the compounds of formula (I) of the present invention may have asymmetric centers and racemates, racemic mixtures and individual diastereomers, and all such isomers, including stereoisomers and geometric isomers, are encompassed by the present invention. In the present invention, when a compound of formula I or a salt thereof exists in stereoisomeric forms (e.g., which contain one or more asymmetric carbon atoms), individual stereoisomers (enantiomers and diastereomers) and mixtures thereof are included within the scope of the invention. The invention also includes individual isomers of the compounds or salts represented by formula I, as well as mixtures of isomers with one or more chiral centers reversed therein. The scope of the invention includes: mixtures of stereoisomers, and purified enantiomerically or enantiomerically/diastereomerically enriched mixtures. The present invention includes mixtures of stereoisomers in all possible different combinations of all enantiomers and diastereomers. The present invention includes all combinations and subsets of stereoisomers of all specific groups defined above. The invention also includes geometric isomers, including cis and trans isomers, of the compounds of formula I or salts thereof. The "isomer" according to the present invention is preferably a "stereoisomer".
The above preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention without departing from the common general knowledge in the art.
The reagents and starting materials used in the present invention are commercially available.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
The structures of all compounds of the invention can be determined by nuclear magnetic resonance 1 H NMR) and/or mass spectrometric detection (MS).
1 H NMR chemical shifts (. Delta.) are recorded in PPM (1)0 -6 ). NMR was performed on a Bruker AVANCE-400 spectrometer. A suitable solvent is deuterated chloroform (CDCl) 3 ) Deuterated methanol (CD) 3 OD), deuterated dimethylsulfoxide (DMSO-d) 6 ) Tetramethylsilane was used as internal standard (TMS).
Low resolution Mass Spectrometry (MS) was determined by an Agilent 1200HPLC/6120 mass spectrometer with the ion source being an ESI source using XBridge C18,4.6 x 50mm,3.5 μm, acid method: solvent A:0.01% trifluoroacetic acid (TFA) in water; solvent B:0.01% trifluoroacetic acid in acetonitrile; the percentages are the volume percent of solute in solution. An alkaline method: solvent A:10mM ammonium bicarbonate in water; solvent B: and (3) acetonitrile.
All compounds of the invention can be separated by a high performance liquid chromatograph, silica gel column chromatography, a thin layer silica gel plate and a rapid separator.
Flash system/Cheetah Flash column chromatography TM ) Agela Technologies MP200 is used, and Flash column Silica-CS (80 g) and Cat No. CS140080-0 are used as a matched separation column.
High performance liquid chromatograph (prep-HPLC) liquid chromatography was prepared using shimadzu LC-20, and detection wavelength: 214nm and 254nm; flow rate: 9.0 mL/min. The chromatographic column comprises: waters xbridge Pre C18, 10um,19mm × 260mm. Elution conditions (alkaline method): solvent A:10mM aqueous ammonium bicarbonate solution, solvent B: acetonitrile, elution gradient 1: a mobile phase A: 80-25% (v/v%), elution gradient 2: mobile phase B: 15-65% (v/v%); elution conditions (acid method): solvent A:0.05% aqueous trifluoroacetic acid, mobile phase B: acetonitrile; elution gradient: mobile phase B: 90-30% (v/v%).
The thin-layer silica gel plate is a tobacco stage yellow sea HSGF254 or Qingdao GF254 silica gel plate. The column chromatography is carried out by using 200-300 mesh silica gel of the yellow sea of Taiwan tobacco as carrier.
All compounds of the invention can be analyzed by Ultra Performance Liquid Chromatography (UPLC) using a Waters acquisition Hclass platform, columns: waters acquisition UPLC beam Shield RP 18.1 mm x 100mm,1.7 μm, mobile phase a: acetonitrile, mobile phase B:5mm potassium dihydrogen phosphate in water (pH adjusted to 2.5 with phosphoric acid). Gradient elution time 15min, flow rate: 0.4mL/min, detection wavelength: 214nm and 254nm; column temperature: 40 ℃; the sample volume is 1 mu L; gradient elution conditions are as follows:
time (minutes) | Velocity phase A (%) | Velocity phase B (%) |
0.00 | 10 | 90 |
5.00 | 40 | 60 |
7.00 | 90 | 10 |
13.00 | 90 | 10 |
13.10 | 10 | 90 |
15.00 | 10 | 90 |
Example 1: synthesis of Compound 1a/1b
Step 1: to a solution of 1,4-dioxaspiro [4.5] decan-8-one (6.0g, 38.4 mmol), N-phenylbis (trifluoromethanesulfonimide) (16.5g, 46.1 mmol) in methyl tert-butyl ether (95 mL) at-78 ℃ under nitrogen protection was added dropwise a solution of sodium bis (trimethylsilyl) amide in tetrahydrofuran (2.0M, 23mL) and, after completion, the reaction was stirred for 1 hour. The reaction was then warmed to room temperature and stirred overnight. The reaction was quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate (100 mL × 3), the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by Flash column chromatography (petroleum ether/ethyl acetate = 10/1) to give compound 1.1 (10.8 g, yield: 97%) as a yellow oil.
Step 2: compound 1.1 (8.0g, 27.8mmol), bis-pinacolborate (9.17g, 36.1mmol), potassium acetate (8.18g, 83.3mmol), sodium bromide (1.14g, 11.1mmol) and Pd (dppf) Cl 2 (1.0 g,1.4 mmol) of a 1,4-dioxane (100 mL) mixture was stirred at reflux overnight. The reaction system was then cooled to room temperature, the solvent was removed under reduced pressure, and the residue was purified by Flash column chromatography (petroleum ether/ethyl acetate = 8/1) to obtain compound 1.2 (4.7 g, yield: 55%) as a yellow oil.
And step 3: under nitrogen protection, compound 1.2 (3.22g, 12.1mmol), 4-chloro-6-fluoroquinoline (2.1g, 13.8mol), potassium carbonate (3.85g, 27.3mmol) and Pd (PPh) 3 ) 4 (0.22g, 0.19mmol) of water/1,4-dioxane (50ml, 4.
And 4, step 4: to a solution of compound 1.3 (2.0 g, 7.02mmol) in isopropanol (30 mL) was added Pd/C (200mg, 10%), and the reaction was stirred under a hydrogen atmosphere (hydrogen balloon) at 55 ℃ overnight. However, the device is not suitable for use in a kitchenThereafter, the reaction system was filtered through Celite to remove Pd/C, and the filtrate was concentrated under reduced pressure to give compound 1.4 (1.9 g, yield: 90%) as a yellow oil. M/z [ M + H ]] + 288.0。
And 5: a mixture of compound 1.4 (2.0 g, 6.97mmol) and hydrochloric acid (6.0M, 5 mL) in acetone (20 mL) was stirred at 45 ℃ for 48 hours. Then, the reaction system was concentrated under reduced pressure, the residue was adjusted to pH =8 to 9 with an aqueous solution of sodium hydroxide (6M), the mixture was extracted with ethyl acetate (30 mL × 3), the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by Flash column chromatography (petroleum ether/ethyl acetate =4/1 to 2/1) to obtain compound 1.5 (750 mg, yield: 44%) as a yellow solid.
Step 6: to a mixed solution of compound 1.5 (750mg, 3.09mmol) and p-toluenesulfonylmethylitrile (TosMIC) (784mg, 4.02mmol) in ethylene glycol dimethyl ether (20 mL) and ethanol (2 mL) under ice-bath conditions was added potassium tert-butoxide (943mg, 7.73mmol). The reaction was stirred at room temperature overnight, quenched with aqueous ammonium chloride solution, and then extracted with ethyl acetate (30 mL. Times.3) to separate the organic phase. The organic phase was washed with saturated brine, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by Flash column chromatography (petroleum ether/ethyl acetate = 3/1) to give compound 1.6a (263 mg, less polar, single stereoisomer) and 1.6b (300 mg, more polar, single stereoisomer) as colorless oils.
And 7: to a solution of compound 1.6a (300mg, 1.18mmol) in methanol (12 mL) was added Raney nickel (wet weight, 0.5 g) under nitrogen, and the reaction system was replaced with hydrogen gas for 3 times, followed by stirring at 45 ℃ for 7 hours. After TLC (petroleum ether/ethyl acetate = 3/1) monitored disappearance of the reaction raw material, the system was filtered with celite, and the filtrate was concentrated under reduced pressure to give compound 1a (280 mg, yield: 92%) as a pale yellow oil. M/z: [ M + H] + 259.0。
Example 2: synthesis of Compound 2
Step 1: to a mixed solution of methyl 3- (6-chloro-2- (trifluoromethoxy) pyridin-3-yl) -3-oxopropanoate (2.2 g, 7.39mmol) in tetrahydrofuran (10 mL) and methanol (10 mL) was added sodium borohydride (84mg, 2.22mmol) portionwise under ice bath conditions, the reaction system was stirred at 0 ℃ for 30 minutes, then the reaction was quenched with water (10 mL), extracted with ethyl acetate (50mL. Times.2), the combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 2.1 (2.2 g, yield: 99%) as an off-white solid. M/z [ M + H ]] + 300.0。
Step 2: compound 2.1 (2.2 g, 7.34mmol) was dissolved in toluene (50 mL), p-toluenesulfonic acid monohydrate (1.4 g, 7.34mmol) was added, the reaction was refluxed at 150 ℃ for 10 hours, most of toluene was removed by concentration under reduced pressure, ethyl acetate (200 mL) was added, and the mixture was washed with saturated sodium bicarbonate solution (50 mLx 2) and saturated brine, respectively, dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product, which was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 4/1) to give compound 2.2 (400 mg, yield: 19%) as a pale yellow solid. 1 H NMR(400MHz,CDCl 3 ):δ7.90(d,J=8.4Hz,1H),7.73(d,J=16.4Hz,1H),7.28(d,J=8.4Hz,1H),6.52(d,J=16.4Hz,1H),3.84(s,3H)。
And step 3: compound 2.2 (200mg, 0.71mmol) and p-toluenesulfonylmethylisocyanogen (208mg, 1.07mmol) were dissolved in anhydrous tetrahydrofuran (15 mL), potassium tert-butoxide (239mg, 2.13mmol) was added in portions under ice-bath conditions, the resulting mixture was stirred at 0 ℃ for 3 hours, quenched with water, extracted with ethyl acetate (20 mLx 2), the combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated and purified with silica gel preparation plates (petroleum ether/ethyl acetate = 10/1-1/1) to give compound 2.3 (138 mg, yield: 61%) as an off-white solid. M/z [ M + H ]] + 321.0。
And 4, step 4: compound 2.3 (138mg, 0.43mmol) was dissolved in methanol (5 mL), ammonium formate (109mg, 1.73mmol) and 10% palladium on carbon (20 mg) were added, the reaction system was heated under reflux under a hydrogen atmosphere (1 atmosphere) for 16 hours, then the reaction solution was filtered with celite, the filter cake was sufficiently washed with ethyl acetate, and the filtrate was concentrated to give compound 2.4 (64 mg, crude) as an off-white solid.
And 5: compound 2.4 (64 mg, crude) was dissolved in tetrahydrofuran (5 mL), N-chlorodicarboximide (27mg, 0.20mmol) was added, the reaction system was stirred at 80 ℃ for 6 hours, then the reaction was quenched with water, the aqueous phase was extracted with ethyl acetate, the combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by Flash column chromatography (petroleum ether/ethyl acetate =10/1 to 3/1) to give compound 2.5 (40 mg, yield: 57%) as a white solid. M/z: [ M + H] + 321.0。
Step 6: a solution of Compound 2.5 (40mg, 0.13mmol) and aqueous sodium hydroxide (4M, 3mL) in ethanol (3 mL) was stirred under reflux for 1 hour. The reaction was then cooled to room temperature and concentrated under reduced pressure to remove the solvent. The residue was adjusted to pH 4-5 with hydrochloric acid (1M), filtered, and the filter cake was dried under vacuum to give 5-chloro-4- (2- (trifluoromethoxy) pyridin-3-yl) -1H-pyrrole-3-carboxylic acid (compound 2, 30mg, crude) as a white solid. M/z [ M + H ]] + 327.0。
Example 3: synthesis of Compound 3
Step 1: bromoacetone (2.0g, 14.7mmol), ethyl cyanoacetate (1.66g, 14.7mmol), sodium ethoxide (1 g, 14.7mmol) and diisopropylethylamine (1.89g, 14.7mmol) were dissolved in anhydrous tetrahydrofuran (40 mL), and the reaction solution was stirred at room temperature overnight. The reaction solution was diluted with ethyl acetate and washed with a saturated aqueous sodium bicarbonate solution. The organic phase was separated, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Flash column chromatography (30% ethyl acetate/petroleum ether) to give compound 3.1 (1.5 g, yield: 60%) as a yellow oil.
Step 2: compound 3.1 (1.2g, 7.09mmol) was dissolved in a mixed solvent of methyl t-butyl ether (3 mL) and methylene chloride (2 mL), and the above solution was slowly added dropwise to a solution of hydrobromic acid (33%, 12 mL) in acetic acid at 5 ℃The resulting mixture was stirred at this temperature for 15 minutes. TLC (petroleum ether/ethyl acetate = 4/1) detects compound 8.1 reaction completion. The reaction mixture was extracted with dichloromethane, the organic phase was separated and concentrated. The residue was purified by Flash column chromatography (30% ethyl acetate/petroleum ether) to give compound 3.2 (900 mg, yield: 56%) as a yellow solid. M/z: [ M + H] + 233.0。
And 3, step 3: a suspension of compound 3.2 (200mg, 0.86mmol), (2-methoxypyridin-3-yl) boronic acid (263mg, 1.72mmol), potassium carbonate (356mg, 2.58mmol), palladium tetrakistriphenylphosphine (92.4mg, 0.08mmol) in 1,4 dioxane (3 mL) and water (1 mL) was reacted with microwave at 120 ℃ for 1 hour. The reaction solution was then filtered, and the filtrate was extracted with ethyl acetate, the organic phase was separated and concentrated. The residue was purified by Flash column chromatography (30% ethyl acetate/petroleum ether) to give compound 3.3 (200 mg, yield: 81%) as a yellow solid. M/z [ M + H ]] + 261.0。
And 4, step 4: a solution of compound 3.3 (200mg, 0.77mmol) and aqueous sodium hydroxide (4M, 3mL) in ethanol (3 mL) was stirred at 100 ℃ for 6 hours. Then, the pH =3 to 4 was adjusted with hydrochloric acid (2M), the mixture was extracted with ethyl acetate, the organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by Flash column chromatography (60% ethyl acetate/petroleum ether) to give 4- (2-methoxypyridin-3-yl) -5-methyl-1H-pyrrole-3-carboxylic acid (compound 3, 53mg, yield: 30%) as a yellow oil. M/z [ M + H ]] + 233.2。
Example 4: synthesis of Compound 11
Step 1: to a mixed solution of 6-chloro-3- (trifluoromethoxy) pyridine-2-carboxylic acid (108mg, 0.45mmol) in tetrahydrofuran (3 mL) and acetonitrile (12 mL) was added N, N' -carbonyldiimidazole (146mg, 0.90mmol) under nitrogen protection, and the reaction was stirred at room temperature for 0.5 hours. Then, potassium monomethyl malonate (141mg, 0.90mmol), triethylamine (137mg, 1.35mmol) and magnesium chloride (190mg, 2.03mmol) were added to the reaction solution, and the resulting mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated to dryness, and then quenched with hydrochloric acid (1M) and adjusted to PH =7 to 8. Extraction was performed with ethyl acetate (100 mL. Times.3), and the combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by Flash column chromatography (petroleum ether/ethyl acetate =4/1 to 1/1) to give compound 11.1 (60 mg, yield: 45%) as a pale yellow oil.
Step 2: under ice-bath conditions, sodium hydrogen (60%, 12mg, 0.30mmol) was added in portions to a solution of compound 11.1 (60mg, 0.20mmol) in tetrahydrofuran (5 mL) under nitrogen protection, and the reaction was stirred at 0 ℃ for 0.5 h. Then, 2-bromo-1-cyclopropylethanone (50mg, 0.30mmol) was added to the reaction solution, which was then heated under reflux for 2 hours. The reaction solution was then quenched by pouring it into saturated aqueous ammonium chloride solution, and the resulting mixture was extracted with ethyl acetate (50 mL. Times.3). The organic phases were combined and washed with brine. The organic phase was separated and dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 11.2 (76 mg, yield: 100%) as a yellow oil.
And step 3: compound 11.2 (76mg, 0.20 mmol) and ammonium acetate (46mg, 0.60mmol) were added to ethanol (3 mL) under reflux for 6 hours under nitrogen, then the reaction was concentrated, ethyl acetate was added to the residue, and then washed with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by Flash column chromatography (petroleum ether/ethyl acetate = 10/1) to give compound 11.3 (37 mg, yield: 51%) as a yellow oil.
And 4, step 4: compound 11.3 (37mg, 0.10mmol), ammonium formate (25mg, 040mmol) and palladium on charcoal (20mg, 10%) were added to methanol (3 mL), the reaction system was replaced with hydrogen gas 3 times, and then refluxed under a hydrogen atmosphere for 1 hour, after which the reaction system was cooled to room temperature and filtered with celite, and the filtrate was concentrated. To the residue was added ethyl acetate, which was washed with water and saturated brine, respectively, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 11.4 (33.5 mg, yield: 100%) as a yellow oil.
And 5: a solution of Compound 11.4 (33.5mg, 0.10mmol) and an aqueous sodium hydroxide solution (4M, 3mL) in methanol (3 mL) was addedThe mixture was stirred under reflux for 2 hours. Then, the reaction system was cooled to room temperature, and water (40 mL) was added to the reaction system, followed by concentration under reduced pressure to remove the organic solvent. The residue was adjusted to pH 3 to 4 with hydrochloric acid (1M), stirred for 30 minutes, and then the aqueous phase was extracted with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give 5-cyclopropyl-2- (3- (trifluoromethoxy) pyridin-2-yl) -1H-pyrrole-3-carboxylic acid (compound 11, 33mg, yield: 100%) as a yellow oil. M/z [ M + H ]] + 313.2。
Example 5: synthesis of Compound 12
Synthesis of 2-bromo-1- (1-methylcyclopropyl) ethanone: 1-methylcyclopropylmethyl ketone (1.0 g, 10.2mmol) was dissolved in methanol (10 mL), and the reaction was cooled to 0 ℃. Liquid bromine (1.6 g, 10.2mmol) was slowly added dropwise. The reaction solution was stirred at 0 ℃ for 2 hours. The reaction was quenched by the addition of water (10 mL). Extraction with dichloromethane was performed, organic phases were combined and washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was separated by Flash column chromatography (petroleum ether/ethyl acetate =100/1 to 10/1) to give 2-bromo-1- (1-methylcyclopropyl) ethanone (compound 12, 790mg, yield: 44%) as a pale yellow oil.
By using the synthesis method of the compound 11.3, 6-chloro-3- (trifluoromethoxy) pyridine-2-carboxylic acid in the step 1 is replaced by 3- (trifluoromethoxy) pyridine-2-carboxylic acid, 2-bromo-1-cyclopropylethanone in the step 2 is replaced by 2-bromo-1- (1-methylcyclopropyl) ethanone to obtain a compound 12.3, and by using the synthesis method of the compound 11, the compound 12.3 is reacted to obtain 5- (1-methylcyclopropyl) -2- (3- (trifluoromethoxy) pyridine-2-yl) -1H-pyrrole-3-carboxylic acid (the compound 12) as a white solid.
Example 6: synthesis of Compound 13
By using the synthesis method of the compound 12, 2-bromo-1- (1-methylcyclopropyl) ethanone in the step 2 is replaced with 2-bromo-1-cyclobutylethylketone to obtain 5-cyclobutyl-2- (3- (trifluoromethoxy) pyridin-2-yl) -1H-pyrrole-3-carboxylic acid (compound 13) as a white solid.
Example 7: synthesis of Compound 14
Step 1: compound 11.4 (155mg, 0.48mmol) was dissolved in acetone (4 mL), potassium carbonate (133mg, 0.96mmol) and methyl iodide (82 mg) were added, respectively, and the reaction solution was heated to 60 ℃ and stirred for 12 hours. The reaction was quenched with water and extracted with ethyl acetate, the organic phases were combined and washed with saturated brine, the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by Flash column chromatography (petroleum ether/ethyl acetate = 4/1) to give compound 14.1 (45 mg, yield: 28%) as a brown oil.
Step 2: compound 14.1 (45mg, 0.13mmol) was added to a mixed solution of ethanol (2 mL) and aqueous sodium hydroxide (4M, 2mL), and the reaction was stirred under reflux for 1 hour. The reaction solution was concentrated to remove the solvent, and then pH =3 to 4 was adjusted with hydrochloric acid (6M). The aqueous phase was extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give 5-cyclopropyl-1-methyl-2- (3- (trifluoromethoxy) pyridin-2-yl) -1H-pyrrole-3-carboxylic acid (compound 14, 30mg, yield: 71%) as a brown oil. M/z [ M + H ]] + 313.2。
Example 8: synthesis of Compound 15
Synthesis of 1-bromo-3-hydroxy-3-methylbutan-2-one: after 3-hydroxy-3-methylbutan-2-one (1.0g, 9.8mmol) was dissolved in diethyl ether (20 mL), a solution of bromine in diethyl ether (5 mL,1.25g, 7.8mmol) was slowly dropped at room temperature, and after completion of the addition, the reaction mixture was stirred at room temperature for 10 minutes, whereupon the color of the solution changed from dark red to light yellow. The reaction solution was concentrated to give 1-bromo-3-hydroxy-3-methylbutan-2-one (1.8 g) as a yellow oil. 1 H NMR(400MHz,CDCl 3 ):δ4.71(s,2H),1.25(s,6H)。
The 2-bromo-1-cyclopropyl group in the step 2 is synthesized by using a compound 11 synthesis methodThe replacement of the ethanone by 1-bromo-3-hydroxy-3-methylbutan-2-one gave a mixture of 5- (2-hydroxypropan-2-yl) -2- (3- (trifluoromethoxy) pyridin-2-yl) -1H-pyrrole-3-carboxylic acid and 5- (prop-1-en-2-yl) -2- (3- (trifluoromethoxy) pyridin-2-yl) -1H-pyrrole-3-carboxylic acid (1/2, compound 15, partial elimination of the 2-hydroxypropan-2-yl group under basic conditions in the last step) as a white solid. M/z: [ M + H] + 313.2,331.2。
Example 9: synthesis of Compound 16
Synthesis of 2-bromo-1- (oxetan-3-yl) ethanone: a synthesis method of 2-bromo-1- (1-methylcyclopropyl) ethanone comprises reacting 1- (oxetan-3-yl) ethanone to obtain 2-bromo-1- (oxetan-3-yl) ethanone. 1 H NMR(400MHz,CDCl 3 ):δ4.87-4.76(m,4H),3.97-3.87(m,1H),2.18(s,3H)。
Using the synthesis method of compound 11, 2-bromo-1-cyclopropylethanone in step 2 was replaced with 2-bromo-1- (oxetan-3-yl) ethanone to give 5- (oxetan-3-yl) -2- (3- (trifluoromethoxy) pyridin-2-yl) -1H-pyrrole-3-carboxylic acid (compound 16) as a white solid. M/z: [ M + H] + 329.0。
Example 10: synthesis of Compound 17
Using the synthetic method of compound 14, the iodomethane in step 1 was replaced with 2-iodopropane to give 5-cyclopropyl-1-isopropyl-2- (3- (trifluoromethoxy) pyridin-2-yl) -1H-pyrrole-3-carboxylic acid (compound 17) as a white solid. M/z: [ M + H] + 355.2。
Example 11: synthesis of Compound 18
By using the synthesis method of compound 11, 2-bromo-1-cyclopropylethanone in step 2 was replaced with 4-hydroxy-3,3-dimethyl-butan-2-one to give 5- (1-hydroxy-2-methylpropan-2-yl) -2- (3- (trifluoromethoxy) pyridin-2-yl) -1H-pyrrole-3-carboxylic acid (compound 18) as a white solid. M/z: [ M + H] + 359.2。
Example 12: synthesis of Compound 19
Synthesis of 1-Cbz-3- (2-bromoacetyl) azetidine:
step 1&2: under ice-bath conditions, 2 drops of N, N-dimethylformamide were added dropwise to a solution of 1-Cbz-azetidine-3-carboxylic acid (1.0 g,4.5 mmol) and oxalyl chloride (1.62g, 12.8 mmol) in dichloromethane (20 mL), and after completion of addition, the reaction was stirred at 0 ℃ for 15 minutes, then warmed to room temperature and stirred for 2 hours. The reaction solution was directly concentrated under reduced pressure, the residue was dissolved in anhydrous tetrahydrofuran (20 mL), trimethylsilyldiazomethane (5.4 mL,2.5M in n-hexane) was added dropwise under ice-bath conditions, and the reaction system was stirred at room temperature overnight. The reaction solution was then concentrated under reduced pressure, and the residue was dissolved in ethyl acetate. The organic phase was washed with saturated aqueous sodium bicarbonate and saturated brine, the organic phase was separated and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 1-Cbz-3- (2-diazoacetyl) azetidine (1.3 g, crude) as a yellow oil. M/z: [ M + H] + 260.0。
And step 3: hydrobromic acid (0.6 mL of a 48% aqueous solution) was added dropwise to a solution of 1-Cbz-3- (2-diazoacetyl) azetidine (1.3 g) in diethyl ether (20 mL) under ice-bath conditions, and the reaction was stirred at 0 ℃ for 1 hour. The reaction solution was adjusted to pH 8 with saturated sodium bicarbonate. The aqueous phase was extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by Flash column chromatography (petroleum ether/ethyl acetate =8/1 to 2/1) to give 1-Cbz-3- (2-bromoacetyl) azetidine (980 mg, yield: 73%) as a colorless oil. M/z [ M + H ]] + 312.0。
Step 1: under nitrogen, compound 11.1 (500mg, 1.70mmol) was added to acetone (20 mL) and the reaction was cooled to 0 ℃. Potassium carbonate (705mg, 5.1mmol) and 1-Cbz-3- (2-bromoacetyl) azetidine (575mg, 1.87mmol) were added to the above reaction in that orderThe mixture was stirred at room temperature for 1 hour. The reaction was quenched with water and extracted three times with ethyl acetate. The organic phases were combined and washed with brine. The organic phase was separated and concentrated to give compound 19.1 (980 mg, crude) as a yellow oil. M/z [ M + H ]] + 529.0。
Step 2: under nitrogen, compound 19.1 (980 mg) and ammonium acetate (525mg, 6.8mmol) were added to ethanol (20 mL) and stirred at reflux for 4 hours, then the reaction mixture was concentrated, ethyl acetate was added to the residue, and the organic phase was washed with saturated brine. The organic phase was separated and concentrated. The residue was purified by Flash column chromatography (petroleum ether/ethyl acetate =8/1 to 2/1) to give compound 19.2 (345 mg, yield: 40%) as a yellow oil. M/z: [ M + H] + 510.2。
And step 3: compound 19.2 (115mg, 0.23mmol) was added to a mixed solution of ethanol (2.5 mL) and aqueous sodium hydroxide (2.5 mL, 4M), and the reaction mixture was stirred under reflux for 1 hour. After cooling to room temperature, di-tert-butyl dicarbonate (100mg, 0.46mmol) was added to the reaction mixture. After the reaction system was further stirred at room temperature for 1 hour, the reaction mixture was concentrated to remove ethanol and adjusted to pH =3 to 4 with hydrochloric acid (2M). The aqueous phase was extracted three times with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give 5- (1- (tert-butoxycarbonyl) azetidin-3-yl) -2- (6-chloro-3- (trifluoromethoxy) pyridin-2-yl) -1H-pyrrole-3-carboxylic acid (compound 19, 120 mg) as a yellow oil.
Example 13: synthesis of Compound 20
Step 1: dess-Martin oxidant (1.07g, 2.53mmol) was slowly added to a solution of methyl 3- (6-chloro-3- (trifluoromethoxy) pyridin-2-yl) -3-pyruvate (500mg, 1.68mmol) and pyridine (398mg, 5.04mmol) in dichloromethane (30 mL) under ice-bath conditions, and after the addition, the reaction was stirred at room temperature for 3 hours, then a saturated aqueous sodium thiosulfate solution (8 mL) and a saturated aqueous sodium bicarbonate solution (8 mL) were added to the reaction, and stirring was continued at room temperature for 1 hour. Extracting the reaction system with ethyl acetateTake (30 mL. Times.3). The organic phase was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether/ethyl acetate =6/1 to 2/1) to give compound 20.1 (270 mg, yield: 48%) as a yellow oil. M/z: [ M + H] + 312.0。
And 2, step: a solution of compound 20.1 (220mg, 0.71mmol), ammonium acetate (546mg, 7.10mmol) and cyclopropanecarbaldehyde (149mg, 2.12mmol) in acetic acid (3 mL) was stirred at 150 ℃ for 15 minutes under microwave conditions; concentrated under reduced pressure, and the residue was extracted with ethyl acetate (30 mL. Times.3). The organic phase was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether/ethyl acetate = 8/1-1/1) to give compound 20.2 (98mg, 31%) as a white solid. M/z [ M + H ]] + 362.0。
And step 3: a mixture of compound 20.2 (98mg, 0.27mmol), palladium on carbon (20mg, 10%) and ammonium formate (68mg, 1.08mmol) in methanol (20 mL) was replaced with hydrogen gas 3 times, and then the reaction system was stirred under reflux under a hydrogen atmosphere for 1 hour. The reaction was cooled to room temperature, filtered through celite to remove palladium on carbon, and the filtrate was concentrated to give compound 20.3 (110 mg, crude) as a white solid. M/z [ M + H ]] + 328.0。
And 4, step 4: a solution of Compound 20.3 (110mg, 0.27mmol) and aqueous sodium hydroxide (2mL, 4M) in ethanol (2 mL) was stirred at 90 ℃ for 1 hour. The organic solvent was removed by concentration under reduced pressure, the aqueous phase was adjusted to pH 4 to 5 with hydrochloric acid (1M), a solid precipitated, and filtered under reduced pressure to give 2-cyclopropyl-5- (3- (trifluoromethoxy) pyridin-2-yl) -1H-imidazole-4-carboxylic acid (compound 20, 20mg, two-step yield: 54%) as a yellow solid. M/z: [ M + H] + 314.0。
Example 14: synthesis of Compound 21
By using the synthesis method of the compound 20, the cyclopropanecarboxaldehyde in the step 2 is replaced by the ring Ding Jiaquan to obtain the 2-cyclobutyl-5- (3- (trifluoromethoxy) pyridine-2-yl) -1H-imidazole-4-carboxylic acid (compound 21) as a white solid. M/z [ M + H ]] + 328.0。
Example 15: synthesis of Compound 22
A synthetic method using compound 12The 3- (trifluoromethoxy) pyridine-2-carboxylic acid in step 1 was replaced with benzoic acid and the 2-bromo-1- (1-methylcyclopropyl) ethanone in step 2 was replaced with 2-bromo-1-cyclopropylethanone to give 5-cyclopropyl-2-phenyl-1H-pyrrole-3-carboxylic acid (compound 22) as a white solid. M/z [ M + H ]] + 228.2。
Example 16: synthesis of Compound 23
Step 1: to a solution of methyl 2- (6-chloro-3- (trifluoromethoxy) pyridin-2-yl) -5-methyl-1H-pyrrole-3-carboxylate (using the synthesis method of compound 11.3, 2-bromo-1-cyclopropylethanone in step 2 was replaced with bromoacetone) (280mg, 0.84mmol) in N, N-dimethylformamide (5 mL) was added sodium hydride (67.2 mg,1.68mmol, 60%) under ice bath conditions, the reaction was stirred at 0 ℃ for 30 minutes, and then (2-bromoethoxy) (tert-butyl) dimethylsilane (402mg, 1.68mmol) was added to the above reaction. The reaction system was further stirred at room temperature overnight, water was added to quench the reaction and extracted with ethyl acetate, the combined organic phases were washed with saturated brine, the organic phase was separated and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether/ethyl acetate = 10/1-2/1) to give compound 23.1 (450 mg, crude) as a light yellow oil.
Step 2&3: using the synthesis method of compound 11, compound 23.1 is reacted to obtain 1- (2-hydroxyethyl) -5-methyl-2- (3- (trifluoromethoxy) pyridin-2-yl) -1H-pyrrole-3-carboxylic acid (compound 23). M/z [ M + H ]] + 331.2。
Example 17: synthesis of Compound 1-1
To a solution of the compound 11 (33mg, 0.10mmol), the compound 1a (30mg, 0.11mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (40mg, 0.21mmol) in N, N-dimethylformamide (5 mL) were slowly added N, N-diisopropylethylamine (41mg, 0.32mmol) and 4-Dimethylaminopyridine (1.3 mg, 0.01mmol), the reaction system was stirred at 45 ℃ for 2 hours, then quenched with ice water (10 mL), diluted with ethyl acetate (30 mL) and the organic phase separated, washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure and purified by prep-HPLC (basic method, mobile phase B: 15-65% (v/v%)) to give compound 1-1 (UPLC retention time: 7.125 min, 3.9mg, yield: 7%) as a white solid. M/z: [ M + H] + 553.2, 1 H NMR(400MHz,CD 3 OD):δ8.75(d,J=4.4Hz,1H),8.55-8.56(m,1H),8.05-8.09(m,1H),7.80-7.86(m,2H),7.54-7.61(m,2H),7.43-7.46(m,1H),6.25(s,1H),3.34-3.50(m,3H),2.08-2.09(m,1H),1.77-1.92(m,9H),0.89-0.93(m,2H),0.68-0.72(m,2H)。
Example 18: synthesis of Compound 1-2
Compound 1-2 was obtained by replacing compound 11 with compound 12 using the method for the synthesis of compound 1-1 (UPLC retention time: 7.279 min). M/z: [ M + H] + 567.2, 1 H NMR(400MHz,CD 3 OD):δ8.76-8.77(d,J=4.8Hz,1H),8.57-8.59(m,1H),8.07-8.11(m,1H),7.83-7.91(m,2H),7.58-7.63(m,2H),7.46-7.50(m,1H),6.39(s,1H),3.51-3.52(d,J=4.8Hz,2H),3.37-3.38(m,1H),2.07-2.17(m,1H),1.71-1.92(m,8H),1.47(s,3H),0.92-0.96(m,2H),0.73-0.76(m,2H)。
Example 19: synthesis of Compounds 1-3
Using the synthesis method of compound 1-1, compound 11 was replaced with compound 13 to give compound 1-3 (UPLC retention time: 7.361 min). M/z: [ M + H] + 567.2, 1 H NMR(400MHz,CD 3 OD):δ8.76-8.77(d,J=4.4Hz,1H),8.58-8.59(d,J=4.4Hz,1H),8.07-8.11(m,1H),7.83-7.90(m,2H),7.56-7.61(m,2H),7.46-7.49(m,1H),6.46(s,1H),3.50-3.57(m,3H),3.33-3.39(m,1H),2.03-2.39(m,6H),1.79-1.91(m,9H)。
Example 20: synthesis of Compounds 1-4
Using the synthesis of Compound 1-1, compound 11 was replaced with Compound 14 to give Compound 1-4 (UPLC retention time: 7.321 min). M/z [ M + H ]] + 567.2, 1 H NMR(400MHz,CD 3 OD):δ8.73-8.72(d,J=4.0Hz,1H),8.63-8.62(d,J=4.0Hz,1H),8.08-8.04(m,1H),7.87-7.82(m,2H),7.60-7.51(m,3H),6.29(s,1H),3.48(s,3H),3.42-3.39(m,2H),3.35(m,1H),2.05(m,1H),1.84-1.73(m,8H),1.29(s,1H),1.00-0.88(m,2H),0.66(s,2H)。
Example 21: synthesis of Compounds 1-5 and 1-6
By using a synthesis method of a compound 1-1, a compound 11 is replaced by a compound 15 to obtain a mixture of the compounds 1-5 and 1-6, and the mixture is separated by prep-HPLC (alkaline method, mobile phase B: 20-40% (5 min); 40-70% (15 min) (v/v%)) to obtain the compounds 1-5 (peak time: 16-17 min, UPLC retention time: 6.291 min) and 1-6 (peak time: 20-21 min, UPLC retention time: 7.207 min), which are all in single stereo configuration. 1-5: m/z [ M + H ]] + 571.2, 1 H NMR(400MHz,CD 3 OD):δ8.79-8.74(m,1H),8.09-8.06(m,1H),7.86-7.85(m,3H),7.61-7.52(m,3H),6.50(s,1H),3.29-3.27(m,3H),2.17-1.75(m,9H),1.59(s,6H);1-6:m/z:[M+H] + 553.2, 1 H NMR(400MHz,CD 3 OD):δ8.75-8.74(m,1H),8.59-8.58(m,1H),8.08-8.05(m,1H),7.89-7.83(m,2H),7.59-7.48(m,3H),6.69(s,1H),5.40(s,1H),4.96(s,1H),3.50-3.48(m,2H),3.36(s,1H),2.21(s,4H),1.85-1.77(m,8H)。
Example 22: synthesis of Compounds 1-7
Using the synthesis of Compound 1-1, compound 11 was replaced with Compound 16 to give Compound 1-7 (UPLC retention time: 6.047 min). M/z [ M + H ]] + 569.2, 1 H NMR(400MHz,CD 3 OD):δ8.75(d,J=4.8Hz,1H),8.58(d,J=4.4Hz,1H),8.11-8.03(m,1H),7.94-7.78(m,2H),7.65-7.45(m,3H),6.65(s,1H),5.04-4.99(m,4H),4.37(q,J=8.0Hz,1H),3.56-3.45(m,3H),2.06-2.00(m,1H),1.93-1.74(m,8H)。
Example 23: synthesis of Compounds 1-8
Using the synthesis of compound 1-1, compound 11 was replaced with compound 17 to give compound 1-8 (UPLC retention time: 7.604 min). M/z [ M + H ]] + 595.2, 1 H NMR(400MHz,CD 3 OD):δ8.73-8.72(d,J=4.0Hz,1H),8.59-8.58(d,J=4.0Hz,1H),8.08-8.04(m,1H),7.87-7.82(m,2H),7.60-7.50(m,3H),6.32(s,1H),4.38-4.31(m,1H),3.37-3.35(d,J=8.0Hz,2H),3.33-3.32(m,1H),2.03-2.02(m,1H),1.98-1.91(m,1H),1.79-1.72(m,8H),1.48-1.46(m,3H),1.43-1.41(m,3H),1.00-0.95(m,2H),0.79-0.73(m,2H)。
Example 24: synthesis of Compounds 1-9
Using the synthesis of Compound 1-1, compound 11 was replaced with Compound 18 to give Compound 1-9 (UPLC retention time: 6.583 min). M/z [ M + H ]] + 585.2, 1 H NMR(400MHz,CD 3 OD):δ8.98-8.97(m,1H),8.60-8.59(m,1H),8.25-8.15(m,2H),7.92-7.91(m,3H),7.51(m,1H),6.53(s,1H),3.59-3.13(m,5H),2.25-1.75(m,9H),1.33(s,6H)。
Example 25: synthesis of Compounds 1-10
Step 1: compound 1-10-1 (obtained by substituting compound 11 for compound 19 using the synthesis method for compound 1-1) (73mg, 0.1mmol), palladium on carbon (10mg, 10%) and ammonium formate (26mg, 0.42mmol) were added to methanol (15 mL) under reflux for 1 hour under hydrogen conditions. Cooled to room temperature, filtered to remove palladium on carbon, and the filtrate was concentrated to give compound 1-10-2 (70 mg) as a white solid. M/z [ M + H ]] + 668.2。
And 2, step: compound 1-10-2 (70 mg, crude) and trifluoroacetic acid (0.5 mL) were dissolved in dichloromethane (5 mL) and stirred at ambient temperature for 1 hour. The organic solvent was removed under reduced pressure, the pH was adjusted to 7-8 with saturated aqueous sodium bicarbonate solution, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC (alkaline method, mobile phase B: 80-25% (v/v%)) to give compounds 1-10 (UPLC retention time: 4.304 min, 10.1mg, yield: 17%) as off-white solids. M/z: [ M + H] + 568.2; 1 HNMR(400MHz,CD 3 OD):δ8.76-8.78(d,J=4.8Hz,1H),8.60-8.62(d,J=4.8Hz,1H),8.07-8.11(m,1H),7.85-7.92(m,2H),7.49-7.61(m,3H),6.62(s,1H),3.91-4.13(m,5H),3.51-3.53(d,J=8.0Hz,2H),3.36-3.43(m,1H),2.10-2.18(m,1H),1.75-1.95(m,8H)。
Example 26: synthesis of Compounds 1-11
Using the synthesis of Compound 1-1, compound 11 was replaced with Compound 22 to give Compound 1-11 (UPLC retention time: 7.197 min). M/z: [ M + H] + 468.2, 1 H NMR(400MHz,CD 3 OD):δ8.76-8.77(d,J=4.8Hz,1H),8.07-8.09(m,1H),7.87-7.90(m,1H),7.53-7.61(m,4H),7.29-7.39(m,3H),6.12(s,1H),3.45-3.47(d,J=8.0Hz,2H),3.36-3.40(m,1H),2.00-2.09(m,1H),1.74-1.93(m,9H),0.85-0.91(m,2H),0.65-0.71(m,2H)。
Example 27: synthesis of Compounds 1-12 and 1-13
Step 1: to a mixed solution of tetrahydrofuran, water and acetic acid (1/1/1.2, 3.2ml) in which compound 1-12-1 (45mg, 0.078mmol) was obtained by replacing compound 11 with compound 23 using the synthesis method of compound 1-1, was added cerium ammonium nitrate (174mg, 0.31mmol), the reaction system was stirred at room temperature for 2 hours, then diluted with ethyl acetate, adjusted to pH. Gtoreq.7 with a saturated aqueous sodium bicarbonate solution, the organic phase was separated and concentrated under reduced pressure to obtain a mixture (38 mg) of compounds 1-12-2 and 1-12-3 as a pale yellow oily liquid.
Step 2: dissolving the mixture (35 mg) obtained in the step 1 in methanol (1 mL), adding sodium borohydride (5 mg, 0.12mmol), adding the sodium borohydride, stirring the obtained mixture for 20 molecules at room temperature, adding hydrochloric acid (2M) to adjust the pH to be approximately equal to 5, adding saturated sodium bicarbonate solution to adjust the pH to be more than or equal to 7, extracting the aqueous phase by dichloromethane, combining the organic phases, drying by anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure, and purifying the residue by prep-HPLC (acid method) to obtain the compounds 1-12 (UPLC retention time: 5.525 minutes, 35mg, two-step yield: 72%) as off-white solids. [ M + H ]] + 587.0, 1 H NMR(400MHz,D 2 O):δ8.83-8.82(m,1H),8.51-8.50(m,1H),8.15-8.10(m,2H),7.90-7.82(m,3H),7.57-7.53(m,1H),6.51(s,1H),4.59(s,2H),4.18-4.14(m,1H),4.00-3.90(m,1H),3.47-3.24(m,5H),1.92(s,1H),1.70-1.61(m,8H)。
And 3, step 3: compounds 1-12 (10mg, 0.017mmol) were dissolved in pyridine (1.0 mL), p-toluenesulfonyl chloride (10mg, 0.051mmol) was added, the reaction system was stirred at 80 ℃ for 6 hours, the reaction system was concentrated to remove the solvent, and the residue was purified by prep-HPLC (acid method) to give compounds 1-13 (UPLC retention time: 4.186 minutes, 4.6mg, yield: 47%) as off-white solids. [ M + H ]] + 569.1, 1 HNMR(400MHz,D 2 O):δ8.79-8.78(m,1H),8.75-8.74(m,2H),8.50-8.46(m,2H),8.12-8.10(m,1H),8.08-8.07(m,1H),8.04-8.00(m,2H),7.98-7.76(m,3H),7.56-7.52(m,1H),6.84(s,1H),5.91(s,1H),4.18-4.10(m,1H),3.60-3.48(m,1H),3.41-3.22(m,1H),1.95-1.90(m,1H),1.69-1.56(m,9H)。
Example 28: synthesis of Compound 2-1
Using the method for synthesizing Compound 1-1, compound 11 was replaced with Compound 2 to give Compound 2-1 (UPLC retention time: 7.027 min). M/z [ M + H ]] + 547.2, 1 H NMR(400MHz,CD 3 OD):δ8.75-8.76(d,J=4.4Hz,1H),8.22-8.23(m,1H),8.07-8.11(m,1H),7.85-7.91(m,2H),7.54-7.63(m,2H),7.36-7.39(m,1H),7.33(s,1H),3.44(d,J=7.8Hz,2H),3.33-3.34(m,1H),2.04-2.13(m,1H),1.75-1.90(m,8H)。
Example 29: synthesis of Compound 2-2
Compound 2-A is obtained by replacing compound 11 with compound 3 using the synthesis method for compound 1-1.
Step 1: to a mixed solution of compound 2-A (80mg, 0.17mmol) dissolved in tetrahydrofuran (2 mL), acetic acid (3 mL) and water (2 mL) was added cerium ammonium nitrate (371mg, 0.68mmol), the reaction system was stirred at room temperature for 3 hours, the reaction was quenched with a saturated aqueous solution of sodium carbonate and adjusted to pH 8 or more, the aqueous phase was extracted with ethyl acetate, the organic phases were combined and dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 2-B (80 mg, yield: 97%) as an off-white solid.
And 2, step: to a solution of compound 2-B (80mg, 0.16mmol) in methanol (3 mL) was added sodium borohydride (12mg, 0.32mmol), the reaction was stirred at room temperature for 20 minutes, then quenched with hydrochloric acid (2M) and adjusted to pH =6, adjusted to pH =8 with sodium bicarbonate solid, the aqueous phase was extracted with ethyl acetate, the organic phases were combined and dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by prep-HPLC (basic method, mobile phase B: 15-65% (v/v%)) to give compound 2-2 (UPLC retention time: 4.525 minutes, 10mg, yield: 13%) as a white solid。m/z:[M+H] + 489.2, 1 H NMR(400MHz,CD 3 OD):δ8.78-8.79(m,1H),8.11-8.07(m,2H),7.90-7.87(m,1H),7.67-7.53(m,3H),7.31(s,1H),7.03-7.00(m,1H),4.38(s,2H),3.86(s,3H),3.42-3.40(m,2H),1.84(m,1H),1.82-1.74(m,1H),1.38-1.34(m,8H)。
Example 30: synthesis of Compound 3-2
Compound 11 was replaced with Compound 20 using the synthesis of Compound 1-1 to give Compound 3-1 (UPLC retention time: 6.346 min). M/z [ M + H ]] + 554.2, 1 H NMR(400MHz,CD 3 OD):δ8.76-8.77(d,J=4.8Hz,1H),8.62-8.63(d,J=4.8Hz,1H),8.07-8.11(m,1H),7.88-7.91(m,2H),7.56-7.63(m,3H),3.37-3.61(m,3H),2.05-2.12(m,2H),1.76-1.96(m,8H),1.05-1.07(m,4H)。
Example 31: synthesis of Compound 3-2
Using the synthesis of compound 1-1, compound 11 was replaced with compound 21 to give compound 3-2 (UPLC retention time: 6.715 min). M/z [ M + H ]] + 568.2, 1 H NMR(400MHz,CD 3 OD):δ8.76-8.77(d,J=4.8Hz,1H),8.64(s,1H),8.07-8.11(m,1H),7.88-7.92(m,2H),7.57-7.61(m,3H),3.69-3.73(m,1H),3.52-3.63(m,2H),3.36-3.44(m,1H),2.40-2.47(m,4H),2.07-2.19(m,2H),1.75-2.04(m,9H)。
Biological test example: determination of IDO biological Activity
Example 1: IDO inhibition activity assay (IC) based on HeLa cells 50 )
HeLa cell line origin: ATCC was cultured in MEM/EBSS liquid medium, and bovine fetal serum (10% FBS), penicillin-streptomycin (100,000U/L), nonessential amino acids (0.1 mM), and sodium pyruvate (Na-pyruvate) (1.0 mM) were added thereto. The cells were maintained in an incubator at 37 deg.C, 95% humidity and 5% carbon dioxide. IDO is expressed by co-incubation with interferon-gamma (IFN. Gamma.), which metabolizes tryptophan to N-formylkynurenine in the medium. The specific experimental method is as follows:
HeLa cells were seeded in a 96-well plate at 25,000 cells/well containing 100 μ L of medium per well, followed by overnight induction of the cells with IFN γ and a specific concentration of test compound (concentration ranging from 10 μ M to 1nM, which is its final volume in conventional medium of 200 μ L) to allow expression of human recombinant IDO. Following incubation, the supernatant (140. Mu.L) was transferred to a 96-well plate and incubation continued at 50 ℃ for 30 minutes after addition of 6.1N TCA (10. Mu.L) to effect complete hydrolysis of the IDO-produced N-formylkynurenine to kynurenine. The reaction solution was then centrifuged at 2500rpm for 10 minutes to remove solid precipitates, after which the supernatant was transferred to another 96-well plate at 100. Mu.L/well and 100. Mu.L of a 2% (w/v) solution of 4- (N, N-dimethylamino) benzaldehyde in acetic acid was added. After incubation for 10 minutes at room temperature, the yellow kynurenine solution may be recorded by a microplate reader (TECAN Infinite M1000 Pro) as its absorbance at 480 nm.
The percent inhibition at each concentration of test compound was determined by evaluating the reduction of kynurenine in the test compound system using a 0.1% DMSO blank as a reference control, and the data was given in Graph Pad4 obtaining IC by non-linear regression 50 The value is obtained.
The five-membered heteroaromatic ring derivative of the present invention shows the result of the activity test, IC 50 The values are shown in the following table:
example 2: cytochrome oxidase P450 inhibitory Effect test
The inhibition of the CYP3A4 subtype of the compound was assessed by LC-MS/MS. The method comprises mixing test compound with human liver microsome solution containing CYP model substrate, incubating under the condition of adding NADPH, and calculating inhibition IC of the compound on CYP3A4 by measuring the metabolite amount of the model substrate in the reaction solution 50 . The specific experimental method is as follows:
test compounds were prepared as 10mM stock solutions in DMSO, and subsequently diluted to 4mM in acetonitrile. Simultaneously, a corresponding reference inhibitor solution is prepared for CYP subtypes, for example, ketoconazole is used as the reference inhibitor, the reference inhibitor and Ketoconazole are separately prepared (8 mu L inhibitor DMSO stock solution +12 mu L acetonitrile), and the sample prepared under the above conditions is 400X concentration. The above solution was then diluted with DMSO: a mixture of acetonitrile (v/v: 40) was diluted in 3-fold gradient to prepare final test solutions, each test compound was assigned 7 concentration points, and the initial final test concentration was 10uM. NADPH, the CYP enzyme model substrate, and the human liver microsome solution were each diluted to an appropriate concentration with a pre-warmed potassium phosphate buffer (0.1M, pH 7.4). Wherein the human liver microsome solution was purchased from BD Gentest (20 mg/mL, corning, cat # 452161).
Adding 400. Mu.L of human liver microsome solution (0.2 mg/mL) to each well of test compound in a 96-well plate, and then adding 2. Mu.L of the test compound final test sample prepared by gradient dilution; for each well for the reference inhibitor, 200. Mu.L of human liver microsome solution (0.2 mg/mL) and 1. Mu.L of the final test sample were added. The prepared corresponding model substrate is dispensed into a 96-well plate by 15 mu L per well, after the microsome solution is mixed evenly, 30 mu L of test compound/reference inhibitor-human liver microsome mixed solution is taken and transferred into the 96-well plate added with the substrate, mixed evenly and preheated for 5 minutes at 37 ℃, and then 15 mu L of 8mM NADPH solution preheated at 37 ℃ is added for starting the reaction. Each test was provided with a duplicate well control, along with a blank control with no test substance added. Incubating a 96-well plate containing a total volume of 60. Mu.L of the reaction solution at 37 ℃, adding 120. Mu.L of a cold acetonitrile solution containing an internal standard to each well to terminate the reaction after the incubation is finished, and then oscillating the 96-well plate on a microplate oscillator for 5 minutes (600 rpm/min) and placing the plateCentrifuge 6000rpm,4 ℃ and centrifuge for 20 minutes. Then, 40. Mu.L of the supernatant from each well was transferred to another 96-well plate, and 80. Mu.L of ultrapure water was added to each well, and the mixture was mixed by a shaker for 5 minutes (600 rpm/min) and centrifuged at 6000rpm,4 ℃ for 20 minutes. Then LC-MS/MS detection is carried out. The inhibition rate was determined by comparing the amount of model substrate metabolites at each test concentration and without test substance addition, and the IC of the test compound was determined by non-linear regression (non-linear) model analysis in GraphPad Prism 5.0 software with the logarithm of the test concentration as the abscissa and the inhibition rate as the ordinate 50 The value is obtained. The results are given in the following table:
note that ref.a (positive control) in the biological test examples is compound 14-1b disclosed in chinese patent application 201710644418.X, chemical name: 5-methyl-N- (((1r, 4r or 1s, 4s) -4- (2-methylpyridin-4-yl) cyclohexyl) methyl) -2- (pyridin-3-yl) -1H-pyrrole-3-carboxamide.
Claims (14)
1. A five-membered heteroaromatic ring derivative (I), a cis-trans isomer or a pharmaceutically acceptable salt thereof;
wherein the ring A is a pyrrole ring or an imidazole ring, and X, Y, Z is selected from the following combinations:
x is NR 1 Y is CR 2 And Z is CR 3 (ii) a Or X is NR 1 Y is CR 2 And Z is N;
l is CH 2 ;
U and V are each independently selected from CH;
cy is a benzene ring or pyridyl, and is unsubstituted or substituted by 1 to 4 groups selected from halogen and C 1-6 Alkoxy or halo C 1-6 One or more substituents of alkoxy being substituted inAn arbitrary position;
r is substituted or unsubstituted quinolyl; said substituted quinolinyl is substituted at any position with 1F;
R 1 is H, methyl, ethyl, isopropyl or cyclopropyl;
R 2 is C 2-4 Alkenyl or substituted or unsubstituted C 3-6 A cycloalkyl group; when said C is 3-6 Cycloalkyl when substituted is optionally substituted by 1C 1-4 Alkyl substituted at any position;
R 3 is H;
m is 1;
n is 1.
2. The five-membered heteroaromatic ring derivative (I), a cis-trans isomer, or a pharmaceutically acceptable salt thereof according to claim 1, wherein: cy is phenyl or pyridyl; the Cy is unsubstituted or further substituted by 1 to 3 groups selected from halogen and C 1-3 Alkoxy and halogeno C 1-3 One or more substituents in the alkoxy group are substituted at any position;
and/or, R 2 Is prop-1-en-2-yl, 1-methylcyclopropyl, cyclobutyl or cyclopropyl.
4. The five-membered heteroaromatic ring derivative (I), a cis-trans isomer, or a pharmaceutically acceptable salt thereof according to claim 3, wherein: r 5 Is hydrogen, methoxy, trifluoromethoxy, ethoxy or difluoromethoxy;
and/or, R 6 Is hydrogen.
5. The five-membered heteroaromatic ring derivative of claim 1, a cis-trans isomer thereof, or a pharmaceutically acceptable salt thereof, wherein it is a compound represented by general formula (II) or (IV):
a compound represented by the general formula (II):
wherein Cy isR 1 Is hydrogen or methyl; r 2 Is prop-1-en-2-yl, 1-methylcyclopropyl, cyclobutyl or cyclopropyl; r 3 Is H;
a compound represented by the general formula (IV):
8. a process for the preparation of the five-membered heteroaromatic ring derivative (I), a cis-trans isomer or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein the process comprises:
in a solvent, carrying out condensation reaction on a compound I-b and a compound X-1 under the action of alkali;
wherein Cy, X, Y, Z, L, R, U, V, m and n are as defined in any one of claims 1 to 7.
9. A pharmaceutical composition comprising a therapeutically effective amount of an active ingredient and a pharmaceutically acceptable adjuvant; the active ingredient comprises the five-membered heteroaromatic ring derivative (I), a cis-trans isomer thereof or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7.
10. The pharmaceutical composition of claim 9, wherein: in the pharmaceutical composition, the pharmaceutically acceptable auxiliary materials are pharmaceutically acceptable carriers, diluents and/or excipients.
11. Use of the five-membered heteroaromatic ring derivative (I), a cis-trans isomer or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, or a pharmaceutical composition according to claim 9 or 10 for the preparation of an indoleamine 2,3-dioxygenase inhibitor.
12. Use of the five-membered heteroaromatic ring derivative (I), a cis-trans isomer or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, or a pharmaceutical composition according to claim 9 or 10 for the manufacture of a medicament for stimulating T cell proliferation.
13. Use of the five-membered heteroaromatic ring derivative (I), a cis-trans isomer or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, or a pharmaceutical composition according to claim 9 or 10 for the manufacture of a medicament for the treatment, alleviation and/or prevention of a related disorder mediated by indoleamine 2,3-dioxygenase; the 2,3-dioxygenase mediated related diseases are viral infections, cancers or autoimmune diseases.
14. The use of claim 13, wherein: the cancer is one or more of bone cancer, liver cancer, esophagus cancer, stomach cancer, rectal cancer, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, bladder cancer, cervical cancer, testicular cancer, kidney cancer, head and neck cancer, lymph cancer, leukemia and skin cancer; the autoimmune disease is one or more of rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disease, systemic scleroderma, dermatomyositis, nodular vasculitis, nephropathy, endocrine related diseases, liver disease, psoriasis and autoimmune reaction caused by infection; the viral infection is an infection caused by one or more of influenza, hepatitis b virus, hepatitis c virus, human papilloma virus, cytomegalovirus, epstein-barr virus, poliovirus, varicella-zoster virus, coxsackie virus and human immunodeficiency virus.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810148194 | 2018-02-13 | ||
CN2018101481948 | 2018-02-13 | ||
CN201810467187 | 2018-05-16 | ||
CN2018104671874 | 2018-05-16 | ||
CN201811523787 | 2018-12-13 | ||
CN2018115237874 | 2018-12-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110156656A CN110156656A (en) | 2019-08-23 |
CN110156656B true CN110156656B (en) | 2023-04-07 |
Family
ID=67645299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910062130.0A Active CN110156656B (en) | 2018-02-13 | 2019-01-23 | Five-membered heteroaromatic ring derivative, preparation method thereof, pharmaceutical composition and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110156656B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116574105A (en) * | 2018-09-27 | 2023-08-11 | 深圳微芯生物科技股份有限公司 | Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity |
CN114605401B (en) * | 2020-04-28 | 2023-08-22 | 江南大学 | Oxygen-containing five-membered heterocyclic compound, synthesis method, pharmaceutical composition and application |
CN113429396A (en) * | 2021-06-08 | 2021-09-24 | 深圳市祥根生物医药有限公司 | Five-membered heteroaromatic ring derivative and preparation method and application thereof |
CN113651761B (en) * | 2021-08-23 | 2023-06-23 | 上海恩氟佳科技有限公司 | Synthesis method of bixafen precursor |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106999450A (en) * | 2014-11-05 | 2017-08-01 | 弗莱塞斯生物科学公司 | immunomodulator |
WO2017192840A1 (en) * | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
CN107663159A (en) * | 2016-07-29 | 2018-02-06 | 上海迪诺医药科技有限公司 | Polycyclic compound, its pharmaceutical composition and application |
CN107674013A (en) * | 2016-08-02 | 2018-02-09 | 上海迪诺医药科技有限公司 | Polycyclic compound, its preparation method, pharmaceutical composition and application |
-
2019
- 2019-01-23 CN CN201910062130.0A patent/CN110156656B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106999450A (en) * | 2014-11-05 | 2017-08-01 | 弗莱塞斯生物科学公司 | immunomodulator |
WO2017192840A1 (en) * | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
CN107663159A (en) * | 2016-07-29 | 2018-02-06 | 上海迪诺医药科技有限公司 | Polycyclic compound, its pharmaceutical composition and application |
CN107674013A (en) * | 2016-08-02 | 2018-02-09 | 上海迪诺医药科技有限公司 | Polycyclic compound, its preparation method, pharmaceutical composition and application |
Non-Patent Citations (1)
Title |
---|
STN检索报告;Columbus, Ohio, US Registry[Online];《STN Registry》;20041114;第2页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110156656A (en) | 2019-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110156656B (en) | Five-membered heteroaromatic ring derivative, preparation method thereof, pharmaceutical composition and application | |
JP6553748B2 (en) | Fused ring compounds, pharmaceutical compositions and uses thereof | |
CN107556244B (en) | Fused ring compound, pharmaceutical composition and application thereof | |
CN107674013B (en) | Polycyclic compound, preparation method, pharmaceutical composition and application thereof | |
JP6305510B2 (en) | Acyclic cyanoethylpyrazolopyridone as a Janus kinase inhibitor | |
TWI669300B (en) | Pyrimidine derivatives, its preparation method, its pharmaceutical composition and its use in medicine | |
CA2935071A1 (en) | Piperidine-dione derivatives | |
CA2799146A1 (en) | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine | |
JP2016513656A (en) | 3- (Aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer | |
ES2651484T3 (en) | Heterocyclic compound containing nitrogen | |
CN107663159A (en) | Polycyclic compound, its pharmaceutical composition and application | |
CN105764900B (en) | CRTH2 agonist compounds and application thereof | |
CN113387962A (en) | Pyrazolo [3,4-d ] pyrimidine-3-one derivative, pharmaceutical composition and application thereof | |
JP2016514709A (en) | Geminal-substituted cyanoethylpyrazolopyridone as a Janus kinase inhibitor | |
AU2014234908A1 (en) | N-(2-cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors | |
WO2022224278A1 (en) | Compounds as pd1/pd-l1 inhibitors and methods thereof | |
WO2023006019A1 (en) | Polysubstituted benzene pd-l1 inhibitor, composition and use thereof | |
CN109956929B (en) | Heterocyclic derivative, preparation method, pharmaceutical composition and application thereof | |
WO2022208382A1 (en) | Novel dialkoxynaphtho[2,3-c]furan-1(3h)-one derivatives and pharmaceutical composition for preventing or treating respiratory disease or sars-cov-2 infection disease, comprising same | |
CN110467629B (en) | Benzoquinone derivative, pharmaceutical composition and application thereof | |
TW202202500A (en) | Pb2 inhibitor, and preparation method therefor and use thereof | |
CN113880833A (en) | Biphenyl polycyclic derivative inhibitor, preparation method and application thereof | |
CN110066271B (en) | Pyrrole derivative, preparation method thereof, pharmaceutical composition and application thereof | |
JP2022554385A (en) | WDR5 inhibitors and modulators | |
CN110066236B (en) | 1H-pyrrole derivative, preparation method thereof, pharmaceutical composition and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |